IRIS
Contact Us

Advanced Search

Searches using filters for organ/system affected are limited to effects (or tumor sites) used to derive the RfD, RfC, oral slope factor, or inhalation unit risk. Other effects associated with chemicals in the IRIS database that were not used as the basis for a toxicity value are not searchable with organ/system filters. IRIS Advanced Search searches only final IRIS assessments; to look for information on draft assessments, see Quick Check: Assessments in Development. Additional information can be downloaded below by clicking on the “Export to Excel” feature.

Chemical Details

A basic version of this table is available.
ROW CHEMICAL NAME CASRN EXPOSURE ROUTE ASSESSMENT TYPE CRIT EFFECT TUMOR TYPE WOE CHARACTERIZATION TOXICITY VALUE TYPE TOXICITY VALUE
1 Acenaphthene 83-32-9 Oral Noncancer Hepatotoxicity n/a RfD 6 x 10 -2 mg/kg-day
2 Acenaphthylene 208-96-8 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
3 Acephate 30560-19-1 Oral Noncancer Inhibition of brain ChE n/a RfD 4 x 10 -3 mg/kg-day
4 Acetaldehyde 75-07-0 Inhalation Cancer Nasal squamous cell carcinoma or adenocarcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 2.2 x 10 -6 per µg/m3
5 Acetaldehyde 75-07-0 Inhalation Noncancer Degeneration of olfactory epithelium n/a RfC 9 x 10 -3 mg/m3
6 Acetochlor 34256-82-1 Oral Noncancer Salivation, increased ALT and ornithine carbamyl transferase; significant increases in triglyceride and decreased blood glucose levels; histopathological changes in kidneys and testes of males n/a RfD 2 x 10 -2 mg/kg-day
7 Acetone 67-64-1 Oral Noncancer Nephropathy n/a RfD 9 x 10 -1 mg/kg-day
8 Acetonitrile 75-05-8 Inhalation Noncancer Mortality n/a RfC 6 x 10 -2 mg/m3
9 Acetophenone 98-86-2 Oral Noncancer General Toxicity n/a RfD 1 x 10 -1 mg/kg-day
10 Acetyl chloride 75-36-5 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
11 Acifluorfen, sodium 62476-59-9 Oral Noncancer Mortality and kidney lesions n/a RfD 1.3 x 10 -2 mg/kg-day
12 Acrolein 107-02-8 Inhalation Noncancer Nasal lesions n/a RfC 2 x 10 -5 mg/m3
13 Acrolein 107-02-8 Oral Noncancer Decreased survival n/a RfD 5 x 10 -4 mg/kg-day
14 Acrylamide 79-06-1 Oral Cancer thyroid tumors and tunica vaginalis mesotheliomas Likely to be carcinogenic to humans (2005 guidelines)
Oral Slope Factor 8.3 x 10 -1 per mg/kg-day
15 Acrylamide 79-06-1 Inhalation Cancer thyroid tumors and tunica vaginalis mesotheliomas Likely to be carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 1.7 x 10 -4 per µg/m3
16 Acrylamide 79-06-1 Inhalation Noncancer Degenerative nerve changes n/a RfC 6 x 10 -3 mg/m3
17 Acrylamide 79-06-1 Oral Noncancer Degenerative nerve changes n/a RfD 2 x 10 -3 mg/kg-day
18 Acrylic acid 79-10-7 Oral Noncancer Reduced pup weight n/a RfD 5 x 10 -1 mg/kg-day
19 Acrylic acid 79-10-7 Inhalation Noncancer Degeneration of the nasal olfactory epithelium n/a RfC 1 x 10 -3 mg/m3
20 Acrylonitrile 107-13-1 Inhalation Noncancer Degeneration and inflammation of nasal respiratory epithelium; hyperplasia of mucous secreting cells n/a RfC 2 x 10 -3 mg/m3
21 Acrylonitrile 107-13-1 Oral Cancer Brain and spinal cord astrocytomas, Zymbal gland carcinomas and stomach papillomas/ carcinomas B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) (1986 guidelines)
Oral Slope Factor 5.4 x 10 -1 per mg/kg-day
22 Acrylonitrile 107-13-1 Inhalation Cancer Respiratory cancer B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) (1986 guidelines)
Inhalation Unit Risk 6.8 x 10 -5 per µg/m3
23 Adiponitrile 111-69-3 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
24 Alachlor 15972-60-8 Oral Noncancer Hemosiderosis, hemolytic anemia n/a RfD 1 x 10 -2 mg/kg-day
25 Alar 1596-84-5 Oral Noncancer No adverse effects n/a RfD 1.5 x 10 -1 mg/kg-day
26 Aldicarb 116-06-3 Oral Noncancer Sweating as clinical sign of AChe inhibition n/a RfD 1 x 10 -3 mg/kg-day
27 Aldicarb sulfone 1646-88-4 Oral Noncancer Brain ChE inhibition in females n/a RfD 1 x 10 -3 mg/kg-day
28 Aldrin 309-00-2 Inhalation Cancer Liver carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 4.9 x 10 -3 per µg/m3
29 Aldrin 309-00-2 Oral Noncancer Liver toxicity n/a RfD 3 x 10 -5 mg/kg-day
30 Aldrin 309-00-2 Oral Cancer Liver carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.7 x 10 1 per mg/kg-day
31 Ally 74223-64-6 Oral Noncancer Decreased body weight n/a RfD 2.5 x 10 -1 mg/kg-day
32 Allyl alcohol 107-18-6 Oral Noncancer Impaired renal function and increased liver and kidney weights n/a RfD 5 x 10 -3 mg/kg-day
33 Allyl chloride 107-05-1 Inhalation Noncancer Functional and histological peripheral neurotoxicity n/a RfC 1 x 10 -3 mg/m3
34 Aluminum phosphide 20859-73-8 Oral Noncancer Body weight and clinical parameters n/a RfD 4 x 10 -4 mg/kg-day
35 Amdro 67485-29-4 Oral Noncancer Increased organ weights n/a RfD 3 x 10 -4 mg/kg-day
36 Ametryn 834-12-8 Oral Noncancer Liver toxicity n/a RfD 9 x 10 -3 mg/kg-day
37 4-Aminopyridine 504-24-5 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
38 Amitraz 33089-61-1 Oral Noncancer Increased mean blood sugar concentration; slight hypothermia n/a RfD 2.5 x 10 -3 mg/kg-day
39 Ammonia 7664-41-7 Inhalation Noncancer Decreased lung function and respiratory symptoms n/a RfC 5 x 10 -1 mg/m3
40 Ammonium acetate 631-61-8 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
41 Ammonium methacrylate 16325-47-6 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
42 Ammonium sulfamate 7773-06-0 Oral Noncancer Decrease in body weight n/a RfD 2 x 10 -1 mg/kg-day
43 Aniline 62-53-3 Inhalation Noncancer Methemoglobin increase, spleen toxicity n/a RfC 1 x 10 -3 mg/m3
44 Aniline 62-53-3 Oral Cancer Spleen, combined fibrosarcoma, stromal sarcoma, capsular sarcoma and hemangiosarcoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 5.7 x 10 -3 per mg/kg-day
45 Anthracene 120-12-7 Oral Noncancer No observed effects n/a RfD 3 x 10 -1 mg/kg-day
46 Antimony 7440-36-0 Oral Noncancer Longevity, blood glucose, and cholesterol n/a RfD 4 x 10 -4 mg/kg-day
47 Antimony trioxide 1309-64-4 Inhalation Noncancer Pulmonary toxicity, chronic interstitial inflammation n/a RfC 2 x 10 -4 mg/m3
48 Apollo 74115-24-5 Oral Noncancer Liver effects; organ weight changes n/a RfD 1.3 x 10 -2 mg/kg-day
49 Aramite 140-57-8 Inhalation Cancer Neoplastic liver nodules and carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 7.1 x 10 -6 per µg/m3
50 Aramite 140-57-8 Oral Cancer Neoplastic liver nodules and carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 2.5 x 10 -2 per mg/kg-day
51 Aroclor 1016 12674-11-2 Oral Noncancer Reduced birth weights n/a RfD 7 x 10 -5 mg/kg-day
52 Aroclor 1254 11097-69-1 Oral Noncancer Ocular exudate, inflamed and prominent Meibomian glands, distorted growth of finger and toe nails; decreased antibody (IgG and IgM) response to sheep erythrocytes n/a RfD 2 x 10 -5 mg/kg-day
53 Arsenic, Inorganic 7440-38-2 Inhalation Cancer Lung cancer (Brown and Chu, 1983a,b,c; Lee-Feldstein, 1983; Higgins, 1982; Enterline and Marsh, 1982) Carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 4.3 x 10 -3 per µg/m3
54 Arsenic, Inorganic 7440-38-2 Oral Noncancer Ischemic heart disease and type 2 diabetes (see Note) n/a RfD 6 x 10 -5 mg/kg-day
55 Arsenic, Inorganic 7440-38-2 Oral Cancer Bladder Cancer and Lung Cancer Carcinogenic to humans (2005 guidelines)
Oral Slope Factor 3.2 x 10 1 per mg/kg-day
56 Arsine 7784-42-1 Inhalation Noncancer Increased hemolysis, abnormal RBC morphology, and increased spleen weight n/a RfC 5 x 10 -5 mg/m3
57 Asbestos 1332-21-4 Inhalation Cancer Lung cancer and mesothelioma A (Human carcinogen) (1986 guidelines)
Inhalation Unit Risk 2.3 x 10 -1 per f/mL
58 Assure 76578-14-8 Oral Noncancer Liver cell enlargement n/a RfD 9 x 10 -3 mg/kg-day
59 Asulam 3337-71-1 Oral Noncancer Lower ovarian weight, lower liver/body weight n/a RfD 5 x 10 -2 mg/kg-day
60 Atrazine 1912-24-9 Oral Noncancer Decreased body weight gain n/a RfD 3.5 x 10 -2 mg/kg-day
61 Avermectin B1 65195-55-3 Oral Noncancer Increased retinal folds in weanlings, decreased viability and lactation indices, decreased pup body weight, increase of dead pups at birth n/a RfD 4 x 10 -4 mg/kg-day
62 Azobenzene 103-33-3 Oral Cancer Abdominal cavity sarcomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.1 x 10 -1 per mg/kg-day
63 Azobenzene 103-33-3 Inhalation Cancer Abdominal cavity sarcomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 3.1 x 10 -5 per µg/m3
64 Barium and Compounds 7440-39-3 Oral Noncancer Nephropathy n/a RfD 2 x 10 -1 mg/kg-day
65 Baygon 114-26-1 Oral Noncancer Mild cholinergic symptoms and RBD ChE inhibition n/a RfD 4 x 10 -3 mg/kg-day
66 Bayleton 43121-43-3 Oral Noncancer Decreased body weight gain, erythrocyte count and hemoglobin level n/a RfD 3 x 10 -2 mg/kg-day
67 Baythroid 68359-37-5 Oral Noncancer Decreased body weights in males, inflammatory foci in kidneys of females n/a RfD 2.5 x 10 -2 mg/kg-day
68 Benefin 1861-40-1 Oral Noncancer Depressed erythrocyte counts n/a RfD 3 x 10 -1 mg/kg-day
69 Benomyl 17804-35-2 Oral Noncancer Decreased pup weanling weights n/a RfD 5 x 10 -2 mg/kg-day
70 Bentazon (Basagran) 25057-89-0 Oral Noncancer Blood loss into the gastrointestinal tract; coagulation defect in male and female dogs n/a RfD 3 x 10 -2 mg/kg-day
71 Benz[a]anthracene 56-55-3 None Cancer None B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
NA 0 NA
72 Benzaldehyde 100-52-7 Oral Noncancer Forestomach lesions, kidney toxicity n/a RfD 1 x 10 -1 mg/kg-day
73 Benzene 71-43-2 Oral Noncancer Decreased lymphocyte count n/a RfD 4 x 10 -3 mg/kg-day
74 Benzene 71-43-2 Inhalation Cancer Leukemia A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Inhalation Unit Risk 7.8 x 10 -6 per µg/m3
75 Benzene 71-43-2 Inhalation Cancer Leukemia A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Inhalation Unit Risk 2.2 x 10 -6 per µg/m3
76 Benzene 71-43-2 Oral Cancer Leukemia A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 5.5 x 10 -2 per mg/kg-day
77 Benzene 71-43-2 Oral Cancer Leukemia A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 1.5 x 10 -2 per mg/kg-day
78 Benzene 71-43-2 Inhalation Noncancer Decreased lymphocyte count n/a RfC 3 x 10 -2 mg/m3
79 Benzidine 92-87-5 Oral Noncancer Brain cell vacuolization; liver cell alterations in females n/a RfD 3 x 10 -3 mg/kg-day
80 Benzidine 92-87-5 Oral Cancer Bladder tumors A (Human carcinogen) (1986 guidelines)
Oral Slope Factor 2.3 x 10 2 per mg/kg-day
81 Benzidine 92-87-5 Inhalation Cancer Bladder tumors A (Human carcinogen) (1986 guidelines)
Inhalation Unit Risk 6.7 x 10 -2 per µg/m3
82 Benzo[a]pyrene (BaP) 50-32-8 Oral Noncancer Neurobehavioral changes n/a RfD 3 x 10 -4 mg/kg-day
83 Benzo[a]pyrene (BaP) 50-32-8 Oral Cancer forestomach, esophagus, tongue, and larynx tumors Carcinogenic to humans (2005 guidelines)
Oral Slope Factor 2 per mg/kg-day
84 Benzo[a]pyrene (BaP) 50-32-8 Inhalation Cancer Squamous cell neoplasia in the larynx, pharynx, trachea, nasal cavity, esophagus, and forestomach. Carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 1 x 10 -3 per µg/m3
85 Benzo[a]pyrene (BaP) 50-32-8 Inhalation Noncancer Reduced ovulation rate and ovary weight n/a RfC 3 x 10 -6 mg/m3
86 Benzo[a]pyrene (BaP) 50-32-8 Inhalation Noncancer Decreased embryo/fetal survival n/a RfC 2 x 10 -6 mg/m3
87 Benzo[a]pyrene (BaP) 50-32-8 Oral Noncancer Decreased ovarian follicles and ovary weight n/a RfD 4 x 10 -4 mg/kg-day
88 Benzo[a]pyrene (BaP) 50-32-8 Oral Noncancer Decreased thymus weight and serum IgM n/a RfD 2 x 10 -3 mg/kg-day
89 Benzo[b]fluoranthene 205-99-2 None Cancer None B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
NA 0 NA
90 Benzo[g,h,i]perylene 191-24-2 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
91 Benzo[k]fluoranthene 207-08-9 None Cancer None B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
NA 0 NA
92 Benzoic acid 65-85-0 Oral Noncancer No adverse effects observed n/a RfD 4 mg/kg-day
93 Benzotrichloride 98-07-7 Oral Cancer Lung, adenocarcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.3 x 10 1 per mg/kg-day
94 Benzyl chloride 100-44-7 Oral Cancer Thyroid, C-cell adenoma/ carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.7 x 10 -1 per mg/kg-day
95 Beryllium and compounds 7440-41-7 Oral Noncancer Small intestinal lesions n/a RfD 2 x 10 -3 mg/kg-day
96 Beryllium and compounds 7440-41-7 Inhalation Cancer Lung cancer B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) (1986 guidelines)
Carcinogenic potential cannot be determined (1996 guidelines)
Known/likely human carcinogen (1996 guidelines)
Inhalation Unit Risk 2.4 x 10 -3 per µg/m3
97 Beryllium and compounds 7440-41-7 Inhalation Noncancer Beryllium sensitization and progression to CBD n/a RfC 2 x 10 -5 mg/m3
98 Bidrin 141-66-2 Oral Noncancer Decreased pup survival n/a RfD 1 x 10 -4 mg/kg-day
99 Biphenthrin 82657-04-3 Oral Noncancer Tremors n/a RfD 1.5 x 10 -2 mg/kg-day
100 Biphenyl 92-52-4 Oral Cancer Liver adenomas or carcinomas Suggestive evidence of carcinogenic potential (2005 guidelines)
Oral Slope Factor 8 x 10 -3 per mg/kg-day
101 Biphenyl 92-52-4 Oral Noncancer Renal papillary mineralization in male F344 rats n/a RfD 5 x 10 -1 mg/kg-day
102 Bis(2-chloro-1-methylethyl) ether 108-60-1 Oral Noncancer Decrease in hemoglobin and possible erythrocyte destruction n/a RfD 4 x 10 -2 mg/kg-day
103 Bis(2-chloroethoxy)methane 111-91-1 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
104 Bis(chloroethyl)ether (BCEE) 111-44-4 Oral Cancer Hepatomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.1 per mg/kg-day
105 Bis(chloroethyl)ether (BCEE) 111-44-4 Inhalation Cancer Hepatomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 3.3 x 10 -4 per µg/m3
106 Bis(chloromethyl)ether (BCME) 542-88-1 Oral Cancer Respiratory tract tumors A (Human carcinogen) (1986 guidelines)
Oral Slope Factor 2.2 x 10 2 per mg/kg-day
107 Bis(chloromethyl)ether (BCME) 542-88-1 Inhalation Cancer Respiratory tract tumors A (Human carcinogen) (1986 guidelines)
Inhalation Unit Risk 6.2 x 10 -2 per µg/m3
108 Bisphenol A 80-05-7 Oral Noncancer Reduced mean body weight n/a RfD 5 x 10 -2 mg/kg-day
109 Boron and Compounds 7440-42-8 Oral Noncancer Decreased fetal weight (developmental) n/a RfD 2 x 10 -1 mg/kg-day
110 Bromate 15541-45-4 Oral Noncancer Renal effects: urothelial hyperplasia n/a RfD 4 x 10 -3 mg/kg-day
111 Bromate 15541-45-4 Oral Cancer Testicular mesothelioma, renal tubular adenoma and carcinoma, and thyroid follicular cell adenoma and carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Carcinogenic potential cannot be determined (1996 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 7 x 10 -1 per mg/kg-day
112 Brominated dibenzofurans None None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
113 Bromobenzene 108-86-1 Oral Noncancer Hepatocellular cytomegaly in male B6C3F1 mice n/a RfD 8 x 10 -3 mg/kg-day
114 Bromobenzene 108-86-1 Oral Noncancer Hepatocellular cytomegaly in male B6C3F1 mice n/a RfD 2 x 10 -2 mg/kg-day
115 Bromobenzene 108-86-1 Inhalation Noncancer Hepatocellular cytomegaly in female B6C3F1 mice n/a RfC 6 x 10 -2 mg/m3
116 Bromobenzene 108-86-1 Inhalation Noncancer Hepatocellular cytomegaly in female B6C3F1 mice n/a RfC 2 x 10 -1 mg/m3
117 Bromochloromethane 74-97-5 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
118 Bromodichloromethane 75-27-4 Oral Noncancer Renal cytomegaly n/a RfD 2 x 10 -2 mg/kg-day
119 Bromodichloromethane 75-27-4 Oral Cancer Kidney (tubular cell adenoma and tubular cell adenocarcinoma) B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 6.2 x 10 -2 per mg/kg-day
120 p-Bromodiphenyl ether 101-55-3 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
121 Bromoform 75-25-2 Oral Noncancer Hepatic lesions n/a RfD 2 x 10 -2 mg/kg-day
122 Bromoform 75-25-2 Oral Cancer Neoplastic lesions in the large intestine B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 7.9 x 10 -3 per mg/kg-day
123 Bromoform 75-25-2 Inhalation Cancer Neoplastic lesions in the large intestine B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 1.1 x 10 -6 per µg/m3
124 Bromomethane 74-83-9 Inhalation Noncancer Degenerative and proliferative lesions of the olfactory epithelium of the nasal cavity n/a RfC 5 x 10 -3 mg/m3
125 Bromomethane 74-83-9 Oral Noncancer Epithelial hyperplasia of the forestomach n/a RfD 1.4 x 10 -3 mg/kg-day
126 Bromotrichloromethane 75-62-7 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
127 Bromoxynil 1689-84-5 Oral Noncancer No adverse effects n/a RfD 2 x 10 -2 mg/kg-day
128 Bromoxynil octanoate 1689-99-2 Oral Noncancer No effects n/a RfD 2 x 10 -2 mg/kg-day
129 1,3-Butadiene 106-99-0 Inhalation Cancer Leukemia Carcinogenic to humans (1999 guidelines)
Inhalation Unit Risk 3 x 10 -5 per µg/m3
130 1,3-Butadiene 106-99-0 Inhalation Noncancer Ovarian atrophy n/a RfC 2 x 10 -3 mg/m3
131 Butyl benzyl phthalate (BBP) 85-68-7 Oral Noncancer Significantly increased liver-to-body weight and liver-to-brain weight ratios n/a RfD 2 x 10 -1 mg/kg-day
132 Butylate 2008-41-5 Oral Noncancer Increased relative liver weight in male dogs n/a RfD 5 x 10 -2 mg/kg-day
133 t-Butylchloride 507-20-0 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
134 Butylphthalyl butylglycolate (BPBG) 85-70-1 Oral Noncancer No adverse effect n/a RfD 1 mg/kg-day
135 Cacodylic acid 75-60-5 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
136 Cadmium 7440-43-9 Inhalation Cancer Lung, trachea, bronchus cancer deaths B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) (1986 guidelines)
Inhalation Unit Risk 1.8 x 10 -3 per µg/m3
137 Cadmium 7440-43-9 Oral Noncancer Significant proteinuria n/a RfD 1 x 10 -3 mg/kg-day
138 Cadmium 7440-43-9 Oral Noncancer Significant proteinuria n/a RfD 5 x 10 -4 mg/kg-day
139 Calcium cyanide 592-01-8 Oral Noncancer Decreased cauda epididymis weight in male F344/N rats. The RfD for cyanide, free is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. n/a RfD 1 x 10 -3 mg/kg-day
140 Caprolactam 105-60-2 Oral Noncancer Reduced offspring body weight n/a RfD 5 x 10 -1 mg/kg-day
141 Captafol 2425-06-1 Oral Noncancer Kidney and bladder toxicity n/a RfD 2 x 10 -3 mg/kg-day
142 Captan 133-06-2 Oral Noncancer Decreased mean body weights n/a RfD 1.3 x 10 -1 mg/kg-day
143 Carbaryl 63-25-2 Oral Noncancer Kidney and liver toxicity n/a RfD 1 x 10 -1 mg/kg-day
144 Carbofuran 1563-66-2 Oral Noncancer RBC and plasma cholinesterase inhibition, and testicular and uterine effects n/a RfD 5 x 10 -3 mg/kg-day
145 Carbon disulfide 75-15-0 Oral Noncancer Fetal toxicity/ malformations n/a RfD 1 x 10 -1 mg/kg-day
146 Carbon disulfide 75-15-0 Inhalation Noncancer Peripheral nervous system dysfunction n/a RfC 7 x 10 -1 mg/m3
147 Carbon tetrachloride 56-23-5 Oral Cancer Hepatocellular adenoma or carcinoma Likely to be carcinogenic to humans (2005 guidelines)
Oral Slope Factor 7 x 10 -2 per mg/kg-day
148 Carbon tetrachloride 56-23-5 Inhalation Cancer Pheochromocytoma Likely to be carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 6 x 10 -6 per µg/m3
149 Carbon tetrachloride 56-23-5 Oral Noncancer Elevated serum SDH activity n/a RfD 4 x 10 -3 mg/kg-day
150 Carbon tetrachloride 56-23-5 Inhalation Noncancer Fatty changes in the liver n/a RfC 1 x 10 -1 mg/m3
151 Carbosulfan 55285-14-8 Oral Noncancer Decreased body weight n/a RfD 1 x 10 -2 mg/kg-day
152 Carboxin 5234-68-4 Oral Noncancer Reduced weight gain, organ weight changes, increased mortality n/a RfD 1 x 10 -1 mg/kg-day
153 Cerium Oxide and Cerium Compounds 1306-38-3 Inhalation Noncancer Increased incidence of alveolar epithelial hyperplasia in the lungs of male and female rats n/a RfC 9 x 10 -4 mg/m3
154 Chloral hydrate 302-17-0 Oral Noncancer CNS depression and GI irritation in humans n/a RfD 1 x 10 -1 mg/kg-day
155 Chloramben 133-90-4 Oral Noncancer Hepatocyte degeneration n/a RfD 1.5 x 10 -2 mg/kg-day
156 Chlordane (Technical) 12789-03-6 Oral Cancer Hepatocellular carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 3.5 x 10 -1 per mg/kg-day
157 Chlordane (Technical) 12789-03-6 Inhalation Cancer Hepatocellular carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Inhalation Unit Risk 1 x 10 -4 per µg/m3
158 Chlordane (Technical) 12789-03-6 Oral Noncancer Hepatic necrosis n/a RfD 5 x 10 -4 mg/kg-day
159 Chlordane (Technical) 12789-03-6 Inhalation Noncancer Hepatic effects n/a RfC 7 x 10 -4 mg/m3
160 Chlordecone (Kepone) 143-50-0 Oral Noncancer Renal lesions (glomerulosclerosis) in female Wistar rats n/a RfD 3 x 10 -4 mg/kg-day
161 Chlordecone (Kepone) 143-50-0 Oral Cancer liver hepatocellular carcinoma Likely to be carcinogenic to humans (2005 guidelines)
Oral Slope Factor 1 x 10 1 per mg/kg-day
162 Chlorimuron-ethyl 90982-32-4 Oral Noncancer Increase in WBC, decreased in RBC in females, increase in alkaline phosphatase in males n/a RfD 2 x 10 -2 mg/kg-day
163 Chlorine 7782-50-5 Oral Noncancer No observed adverse effects n/a RfD 1 x 10 -1 mg/kg-day
164 Chlorine cyanide 506-77-4 Oral Noncancer Weight loss, thyroid effects, and myelin degeneration n/a RfD 5 x 10 -2 mg/kg-day
165 Chlorine dioxide 10049-04-4 Inhalation Noncancer Vascular congestion and peribronchial edema n/a RfC 2 x 10 -4 mg/m3
166 Chlorine dioxide 10049-04-4 Oral Noncancer Neurodevelopmental effects n/a RfD 3 x 10 -2 mg/kg-day
167 Chlorite (sodium salt) 7758-19-2 Oral Noncancer Neurodevelopmental effects n/a RfD 3 x 10 -2 mg/kg-day
168 1-Chloro-1,1-difluoroethane 75-68-3 Inhalation Noncancer No adverse effects n/a RfC 5 x 10 1 mg/m3
169 2-Chloroacetophenone 532-27-4 Inhalation Noncancer Squamous hyperplasia of the nasal respiratory epithelium n/a RfC 3 x 10 -5 mg/m3
170 p-Chloroaniline 106-47-8 Oral Noncancer Nonneoplastic lesions of splenic capsule n/a RfD 4 x 10 -3 mg/kg-day
171 Chlorobenzene 108-90-7 Oral Noncancer Histopathologic changes in liver n/a RfD 2 x 10 -2 mg/kg-day
172 Chlorobenzilate 510-15-6 Oral Noncancer Decreased stool quantity, food consumption and body weight gains hyperirritability (maternal effects) n/a RfD 2 x 10 -2 mg/kg-day
173 1-Chlorobutane 109-69-3 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
174 2-Chlorobutane 78-86-4 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
175 Chlorocyclopentadiene 41851-50-7 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
176 Chlorodifluoromethane 75-45-6 Inhalation Noncancer Increased kidney, adrenal and pituitary weights n/a RfC 5 x 10 1 mg/m3
177 Chloroform 67-66-3 Inhalation Cancer Hepatocellular carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Likely to be carcinogenic to humans (1999 guidelines)
Not likely to be carcinogenic to humans (1999 guidelines)
Inhalation Unit Risk 2.3 x 10 -5 per µg/m3
178 Chloroform 67-66-3 Oral Noncancer Moderate/marked fatty cyst formation in the liver and elevated SGPT n/a RfD 1 x 10 -2 mg/kg-day
179 Chloromethyl methyl ether (CMME) 107-30-2 None Cancer None A (Human carcinogen) (1986 guidelines)
NA 0 NA
180 beta-Chloronaphthalene 91-58-7 Oral Noncancer Dyspnea, abnormal appearance, liver enlargement n/a RfD 8 x 10 -2 mg/kg-day
181 2-Chlorophenol 95-57-8 Oral Noncancer Reproductive effects n/a RfD 5 x 10 -3 mg/kg-day
182 p-Chlorophenyl methyl sulfide 123-09-1 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
183 p-Chlorophenyl methyl sulfone 98-57-7 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
184 p-Chlorophenyl methyl sulfoxide 934-73-6 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
185 Chloroprene 126-99-8 Inhalation Cancer alveolar/ bronchiolar adenoma or carcinoma hemangioma/ hemangiosarcoma (all organs) mammary gland adenocarcinoma, carcinoma, or adenoacanthoma forestomach squamous cell papilloma or carcinoma hepatocellular adenoma or carcinoma Harderian gland adenoma or carcinoma skin sarcoma and Zymbal's gland carcinoma Likely to be carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 3 x 10 -4 per µg/m3
186 Chloroprene 126-99-8 Inhalation Noncancer Increase in incidence of olfactory atrophy, alveolar hyperplasia, and splenic hematopoietic proliferation in male F344/N rats, female F344/N rats, and female B6C3F1 mice, respectively n/a RfC 2 x 10 -2 mg/m3
187 Chlorothalonil 1897-45-6 Oral Noncancer Renal tubular epithelial vacuolation n/a RfD 1.5 x 10 -2 mg/kg-day
188 o-Chlorotoluene 95-49-8 Oral Noncancer Decrease in body weight gain n/a RfD 2 x 10 -2 mg/kg-day
189 Chlorpropham 101-21-3 Oral Noncancer Kidney, spleen, liver, and bone marrow toxicity n/a RfD 2 x 10 -1 mg/kg-day
190 Chlorsulfuron 64902-72-3 Oral Noncancer Decreased body weight n/a RfD 5 x 10 -2 mg/kg-day
191 Chromium(III), insoluble salts 16065-83-1 Oral Noncancer No effects observed n/a RfD 1.5 mg/kg-day
192 Chromium(VI) 18540-29-9 Oral Noncancer Hyperplasia in small intesting of female mice (chronic exposure study). n/a RfD 9 x 10 -4 mg/kg-day
193 Chromium(VI) 18540-29-9 Inhalation Cancer Lung cancer Carcinogenic to humans (2005 guidelines)
Likely to be carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 1.8 x 10 -2 per µg/m3
194 Chromium(VI) 18540-29-9 Oral Cancer Squamous cell carcinoma or squamous cell papilloma. Carcinogenic to humans (2005 guidelines)
Likely to be carcinogenic to humans (2005 guidelines)
Oral Slope Factor 2.7 x 10 -1 per mg/kg-day
195 Chromium(VI) 18540-29-9 Inhalation Noncancer Ulcerated nasal septum in humans n/a RfC 3 x 10 -5 mg/m3
196 Chromium(VI) 18540-29-9 Oral Noncancer Chronic inflammation in female rats. n/a RfD 7 x 10 -4 mg/kg-day
197 Chromium(VI) 18540-29-9 Oral Noncancer Decreased postnatal growth in F1 offspring in mice (continuous breeding study) n/a RfD 7 x 10 -2 mg/kg-day
198 Chromium(VI) 18540-29-9 Oral Noncancer Decreased hemoglobin in male rats (short-term exposure data). n/a RfD 1 x 10 -2 mg/kg-day
199 Chrysene 218-01-9 None Cancer None B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
NA 0 NA
200 Coke oven emissions None Inhalation Cancer Respiratory cancer A (Human carcinogen) (1986 guidelines)
Inhalation Unit Risk 6.2 x 10 -4 per µg/m3
201 Copper 7440-50-8 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
202 Copper cyanide 544-92-3 Oral Noncancer Decreased body and organ weights, histopathologic alterations in liver and kidney n/a RfD 5 x 10 -3 mg/kg-day
203 Creosote 8001-58-9 None Cancer None B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) (1986 guidelines)
NA 0 NA
204 Crotonaldehyde 123-73-9 None Cancer None C (Possible human carcinogen) (1986 guidelines)
NA 0 NA
205 Cumene 98-82-8 Oral Noncancer Increased average kidney weight in female rats n/a RfD 1 x 10 -1 mg/kg-day
206 Cumene 98-82-8 Inhalation Noncancer Increased kidney weights in female rats and adrenal weights in male and female rats n/a RfC 4 x 10 -1 mg/m3
207 Cyanide, free 57-12-5 Oral Noncancer Decreased cauda epididymis weight in male F344/N rats. The RfD for cyanide, free is presented in section 1.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. n/a RfD 6.3 x 10 -4 mg/kg-day
208 Cyanogen 460-19-5 Oral Noncancer Decreased cauda epididymis weight in male F344/N rats. The RfD for cyanogen is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. n/a RfD 1 x 10 -3 mg/kg-day
209 Cyanogen bromide 506-68-3 Oral Noncancer Weight loss, thyroid effects and myelin degeneration n/a RfD 9 x 10 -2 mg/kg-day
210 Cyclohexane 110-82-7 Inhalation Noncancer Reduced pup weights in the F1 and F2 generations n/a RfC 6 mg/m3
211 Cyclohexanone 108-94-1 Oral Noncancer Body weight depression n/a RfD 5 mg/kg-day
212 Cyclohexylamine 108-91-8 Oral Noncancer Testicular damage n/a RfD 2 x 10 -1 mg/kg-day
213 Cyhalothrin/Karate 68085-85-8 Oral Noncancer Reduced body weight gain preceding pregnancy reduced body weight gain in offspring during weaning period n/a RfD 5 x 10 -3 mg/kg-day
214 Cypermethrin 52315-07-8 Oral Noncancer G.I. tract disturbances n/a RfD 1 x 10 -2 mg/kg-day
215 Cyromazine 66215-27-8 Oral Noncancer Hematologic effects n/a RfD 7.5 x 10 -3 mg/kg-day
216 Dacthal 1861-32-1 Oral Noncancer Effects on the lungs, liver, kidney, thyroid and thyroid hormones in males and females and eyes of females n/a RfD 1 x 10 -2 mg/kg-day
217 Dalapon, sodium salt 75-99-0 Oral Noncancer Increased kidney body weight ratio n/a RfD 3 x 10 -2 mg/kg-day
218 Danitol 39515-41-8 Oral Noncancer Tremors n/a RfD 2.5 x 10 -2 mg/kg-day
219 2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) 1163-19-5 Oral Noncancer Neurobehavioral effects n/a RfD 7 x 10 -3 mg/kg-day
220 2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) 1163-19-5 Oral Cancer Liver neoplastic nodules or carcinoma (combined) Suggestive evidence of carcinogenic potential (2005 guidelines)
Oral Slope Factor 7 x 10 -4 per mg/kg-day
221 Demeton 8065-48-3 Oral Noncancer ChE inhibition, optic nerve degeneration n/a RfD 4 x 10 -5 mg/kg-day
222 Di (2-ethylhexyl)phthalate (DEHP) 117-81-7 Oral Cancer Hepatocellular carcinoma and adenoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.4 x 10 -2 per mg/kg-day
223 Di (2-ethylhexyl)phthalate (DEHP) 117-81-7 Oral Noncancer Increased relative liver weight n/a RfD 2 x 10 -2 mg/kg-day
224 Di(2-ethylhexyl)adipate 103-23-1 Oral Noncancer Changes in body weight and liver weight increased liver weight of male and female parents reduced ossification and slightly dilated ureters in fetuses reduced offspring weight gain, total litter weight, and litter size n/a RfD 6 x 10 -1 mg/kg-day
225 Di(2-ethylhexyl)adipate 103-23-1 Oral Cancer Combined hepatocellular adenomas and carcinomas C (Possible human carcinogen) (1986 guidelines)
Oral Slope Factor 1.2 x 10 -3 per mg/kg-day
226 Dibenz[a,h]anthracene 53-70-3 None Cancer None B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
NA 0 NA
227 Dibenzofuran 132-64-9 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
228 1,2-Dibromo-3-chloropropane (DBCP) 96-12-8 Inhalation Noncancer Testicular effects n/a RfC 2 x 10 -4 mg/m3
229 1,4-Dibromobenzene 106-37-6 Oral Noncancer Liver/body weight ratio and hepatic microsomal enzyme induction n/a RfD 1 x 10 -2 mg/kg-day
230 Dibromochloromethane 124-48-1 Oral Cancer Hepatocellular adenoma or carcinoma C (Possible human carcinogen) (1986 guidelines)
Oral Slope Factor 8.4 x 10 -2 per mg/kg-day
231 Dibromochloromethane 124-48-1 Oral Noncancer Hepatic lesions n/a RfD 2 x 10 -2 mg/kg-day
232 Dibromodichloromethane 594-18-3 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
233 p,p'-Dibromodiphenyl ether 2050-47-7 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
234 1,2-Dibromoethane 106-93-4 Oral Cancer Forestomach tumors, hemangiosarcomas, thyroid follicular cell adenomas or carcinomas Likely to be carcinogenic to humans (1999 guidelines)
Oral Slope Factor 1 mg/kg-day
235 1,2-Dibromoethane 106-93-4 Oral Cancer Forestomach tumors, hemangiosarcomas, thyroid follicular cell adenomas or carcinomas Likely to be carcinogenic to humans (1999 guidelines)
Oral Slope Factor 2 per mg/kg-day
236 1,2-Dibromoethane 106-93-4 Inhalation Cancer Nasal cavity (includes adenoma, adenocarcinoma, papillary adenoma, squamous cell carcinoma, and or/papilloma), hemangiosarcomas, mesotheliomas Likely to be carcinogenic to humans (1999 guidelines)
Inhalation Unit Risk 6 x 10 -4 per µg/m3
237 1,2-Dibromoethane 106-93-4 Inhalation Cancer Nasal cavity (includes adenoma, adenocarcinoma, papillary adenoma, squamous cell carcinoma, and or/papilloma), hemangiosarcomas, mesotheliomas Likely to be carcinogenic to humans (1999 guidelines)
Inhalation Unit Risk 3 x 10 -4 per µg/m3
238 1,2-Dibromoethane 106-93-4 Oral Noncancer Testicular atrophy, liver peliosis, and adrenal cortical degeneration n/a RfD 9 x 10 -3 mg/kg-day
239 1,2-Dibromoethane 106-93-4 Inhalation Noncancer Nasal inflammation n/a RfC 9 x 10 -3 mg/m3
240 Dibutyl phthalate (DBP) 84-74-2 Oral Noncancer Increased mortality n/a RfD 1 x 10 -1 mg/kg-day
241 Dicamba 1918-00-9 Oral Noncancer Maternal (reduced weight gain) and fetal toxicity n/a RfD 3 x 10 -2 mg/kg-day
242 Dichloroacetic acid 79-43-6 Oral Noncancer Lesions observed in the testes, cerebrum, cerebellum, and liver. n/a RfD 4 x 10 -3 mg/kg-day
243 Dichloroacetic acid 79-43-6 Oral Cancer Hepatoadenoma and Hepatocarcinoma Likely to be carcinogenic to humans (1999 guidelines)
Oral Slope Factor 5 x 10 -2 per mg/kg-day
244 1,2-Dichlorobenzene 95-50-1 Oral Noncancer No adverse effects observed n/a RfD 9 x 10 -2 mg/kg-day
245 1,3-Dichlorobenzene 541-73-1 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
246 1,4-Dichlorobenzene 106-46-7 Inhalation Noncancer Increased liver weights in P1 males n/a RfC 8 x 10 -1 mg/m3
247 3,3'-Dichlorobenzidine 91-94-1 Oral Cancer Mammary adenocarcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 4.5 x 10 -1 per mg/kg-day
248 Dichlorodifluoromethane 75-71-8 Oral Noncancer Reduced body weight n/a RfD 2 x 10 -1 mg/kg-day
249 p,p'-Dichlorodiphenyl dichloroethane (DDD) 72-54-8 Oral Cancer Liver tumors B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 2.4 x 10 -1 per mg/kg-day
250 p,p'-Dichlorodiphenyldichloroethylene (DDE) 72-55-9 Oral Cancer Hepatocellular carcinomas, hepatomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 3.4 x 10 -1 per mg/kg-day
251 p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 Inhalation Cancer Liver tumors, benign and malignant B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 9.7 x 10 -5 per µg/m3
252 p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 Oral Cancer Liver tumors, benign and malignant B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 3.4 x 10 -1 per mg/kg-day
253 p,p'-Dichlorodiphenyltrichloroethane (DDT) 50-29-3 Oral Noncancer Liver lesions n/a RfD 5 x 10 -4 mg/kg-day
254 1,1-Dichloroethane 75-34-3 None Cancer None C (Possible human carcinogen) (1986 guidelines)
NA 0 NA
255 1,2-Dichloroethane 107-06-2 Inhalation Cancer Hemangiosarcomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 2.6 x 10 -5 per µg/m3
256 1,2-Dichloroethane 107-06-2 Oral Cancer Hemangiosarcomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 9.1 x 10 -2 per mg/kg-day
257 cis-1,2-Dichloroethylene 156-59-2 Oral Noncancer Increased relative kidney weight in male rats n/a RfD 2 x 10 -3 mg/kg-day
258 trans-1,2-Dichloroethylene 156-60-5 Oral Noncancer Decrease in number of antibody forming cells (AFCs) against sheep red blood cells (sRBCs) in male mice n/a RfD 2 x 10 -2 mg/kg-day
259 1,1-Dichloroethylene (1,1-DCE) 75-35-4 Inhalation Noncancer Liver toxicity (fatty change) n/a RfC 2 x 10 -1 mg/m3
260 1,1-Dichloroethylene (1,1-DCE) 75-35-4 Oral Noncancer Liver toxicity (fatty change) n/a RfD 5 x 10 -2 mg/kg-day
261 Dichloromethane 75-09-2 Oral Cancer Hepatocellular carcinomas or adenomas Likely to be carcinogenic to humans (2005 guidelines)
Oral Slope Factor 3.3 x 10 -3 per mg/kg-day
262 Dichloromethane 75-09-2 Inhalation Noncancer Hepatic effects (hepatic vacuolation) n/a RfC 6 x 10 -1 mg/m3
263 Dichloromethane 75-09-2 Oral Noncancer Hepatic effects (hepatic vacuolation, liver foci) n/a RfD 6 x 10 -3 mg/kg-day
264 Dichloromethane 75-09-2 Inhalation Cancer Hepatocellular carcinomas or adenomas, bronchoalveolar carcinomas or adenomas Likely to be carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 1.7 x 10 -8 per µg/m3
265 2,4-Dichlorophenol 120-83-2 Oral Noncancer Decreased delayed hypersensitivity response n/a RfD 3 x 10 -3 mg/kg-day
266 4-(2,4-Dichlorophenoxy)butyric acid (2,4-DB) 94-82-6 Oral Noncancer Internal hemorrhage, mortality n/a RfD 8 x 10 -3 mg/kg-day
267 2,4-Dichlorophenoxyacetic acid (2,4-D) 94-75-7 Oral Noncancer Hematologic, hepatic and renal toxicity n/a RfD 1 x 10 -2 mg/kg-day
268 1,2-Dichloropropane 78-87-5 Inhalation Noncancer Hyperplasia of the nasal mucosa n/a RfC 4 x 10 -3 mg/m3
269 2,3-Dichloropropanol 616-23-9 Oral Noncancer Myocardial degeneration, hepatotoxicity and nephrotoxicity n/a RfD 3 x 10 -3 mg/kg-day
270 1,3-Dichloropropene 542-75-6 Inhalation Cancer Bronchioalveolar adenoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Inhalation Unit Risk 4 x 10 -6 per µg/m3
271 1,3-Dichloropropene 542-75-6 Inhalation Noncancer Hypertrophy/ hyperplasia of the nasal respiratory epithelium n/a RfC 2 x 10 -2 mg/m3
272 1,3-Dichloropropene 542-75-6 Oral Cancer Hepatocellular adenoma/carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 5 x 10 -2 per mg/kg-day
273 1,3-Dichloropropene 542-75-6 Oral Noncancer Chronic irritation n/a RfD 3 x 10 -2 mg/kg-day
274 1,3-Dichloropropene 542-75-6 Oral Cancer Urinary bladder carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 1 x 10 -1 per mg/kg-day
275 1,3-Dichloropropene 542-75-6 Oral Cancer Hepatocellular adenoma/carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 5 x 10 -2 per mg/kg-day
276 Dichlorvos 62-73-7 Oral Noncancer Plasma and RBC ChE inhibition in males and females brain ChE inhibition in males n/a RfD 5 x 10 -4 mg/kg-day
277 Dichlorvos 62-73-7 Inhalation Noncancer Decreased brain cholinesterase activity n/a RfC 5 x 10 -4 mg/m3
278 Dichlorvos 62-73-7 Oral Cancer Forestomach tumors, pancreatic acinar adenoma, leukemia B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 2.9 x 10 -1 per mg/kg-day
279 Dieldrin 60-57-1 Inhalation Cancer Liver carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 4.6 x 10 -3 per µg/m3
280 Dieldrin 60-57-1 Oral Cancer Liver carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.6 x 10 1 per mg/kg-day
281 Dieldrin 60-57-1 Oral Noncancer Liver lesions n/a RfD 5 x 10 -5 mg/kg-day
282 Diesel engine exhaust None Inhalation Noncancer Pulmonary inflammation and histopathology n/a RfC 5 x 10 -3 mg/m3
283 Diethyl phthalate (DEP) 84-66-2 Oral Noncancer Decreased growth rate, food consumption and altered organ weights n/a RfD 8 x 10 -1 mg/kg-day
284 Diethyl-p-nitrophenylphosphate 311-45-5 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
285 Diethylene glycol dinitrate (DEGDN) 693-21-0 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
286 Difenzoquat 43222-48-6 Oral Noncancer Decreased body weight n/a RfD 8 x 10 -2 mg/kg-day
287 Diflubenzuron 35367-38-5 Oral Noncancer Methemoglobin and sulfhemoglobin formation n/a RfD 2 x 10 -2 mg/kg-day
288 1,1-Difluoroethane 75-37-6 Inhalation Noncancer No adverse effects observed n/a RfC 4 x 10 1 mg/m3
289 Diisopropyl methylphosphonate (DIMP) 1445-75-6 Oral Noncancer No effects related to treatment n/a RfD 8 x 10 -2 mg/kg-day
290 Dimethipin 55290-64-7 Oral Noncancer Increased absolute and relative liver weight n/a RfD 2 x 10 -2 mg/kg-day
291 Dimethoate 60-51-5 Oral Noncancer Brain ChE inhibition n/a RfD 2 x 10 -4 mg/kg-day
292 Dimethyl phthalate 131-11-3 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
293 Dimethyl sulfate 77-78-1 None Cancer None B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
NA 0 NA
294 Dimethyl terephthalate (DMT) 120-61-6 Oral Noncancer Chronic kidney inflammation n/a RfD 1 x 10 -1 mg/kg-day
295 N-N-Dimethylaniline 121-69-7 Oral Noncancer Splenomegaly, increased splenic hemosiderosis and hematopoiesis n/a RfD 2 x 10 -3 mg/kg-day
296 N,N-Dimethylformamide 68-12-2 Inhalation Noncancer Digestive disturbances and minimal hepatic changes suggestive of liver abnormalities n/a RfC 3 x 10 -2 mg/m3
297 2,4-Dimethylphenol 105-67-9 Oral Noncancer Clinical signs (lethargy, prostration, and ataxia) and hematological changes n/a RfD 2 x 10 -2 mg/kg-day
298 2,6-Dimethylphenol 576-26-1 Oral Noncancer Body weight changes and histopathological changes of internal organs (liver, spleen and kidneys) n/a RfD 6 x 10 -4 mg/kg-day
299 3,4-Dimethylphenol 95-65-8 Oral Noncancer Changes in blood pressure and body weight histopathological changes in liver, kidney and spleen n/a RfD 1 x 10 -3 mg/kg-day
300 4,6-Dinitro-o-cyclohexyl phenol 131-89-5 Oral Noncancer Cataract formation n/a RfD 2 x 10 -3 mg/kg-day
301 m-Dinitrobenzene 99-65-0 Oral Noncancer Increased splenic weight n/a RfD 1 x 10 -4 mg/kg-day
302 o-Dinitrobenzene 528-29-0 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
303 2,4-Dinitrophenol 51-28-5 Oral Noncancer Cataract formation n/a RfD 2 x 10 -3 mg/kg-day
304 2,4-Dinitrotoluene 121-14-2 Oral Noncancer Neurotoxicity, Heinz bodies and biliary tract hyperplasia n/a RfD 2 x 10 -3 mg/kg-day
305 2,4-/2,6-Dinitrotoluene mixture Various Oral Cancer Liver: hepatocellular carcinomas, neoplastic nodules; mammary gland: adenomas, fibroadenomas, fibromas, adenocarcinomas/ carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 6.8 x 10 -1 per mg/kg-day
306 Dinoseb 88-85-7 Oral Noncancer Decreased fetal weight n/a RfD 1 x 10 -3 mg/kg-day
307 1,4-Dioxane 123-91-1 Oral Noncancer Liver and kidney toxicity n/a RfD 3 x 10 -2 mg/kg-day
308 1,4-Dioxane 123-91-1 Inhalation Cancer Multiple (nasal, liver, kidney, peritoneal, mammary gland, and Zymbal gland) Likely to be carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 5 x 10 -6 per µg/m3
309 1,4-Dioxane 123-91-1 Oral Cancer Hepatocellular adenoma and carcinoma Likely to be carcinogenic to humans (2005 guidelines)
Oral Slope Factor 1 x 10 -1 per mg/kg-day
310 1,4-Dioxane 123-91-1 Inhalation Noncancer Atrophy and respiratory metaplasia of the olfactory epithelium n/a RfC 3 x 10 -2 mg/m3
311 Diphenamid 957-51-7 Oral Noncancer Liver toxicity n/a RfD 3 x 10 -2 mg/kg-day
312 Diphenylamine 122-39-4 Oral Noncancer Decreased body weight gain, and increased liver and kidney weights n/a RfD 2.5 x 10 -2 mg/kg-day
313 1,2-Diphenylhydrazine 122-66-7 Oral Cancer Hepatocellular carcinomas and neoplastic liver nodules B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 8 x 10 -1 per mg/kg-day
314 1,2-Diphenylhydrazine 122-66-7 Inhalation Cancer Hepatocellular carcinomas and neoplastic liver nodules B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 2.2 x 10 -4 per µg/m3
315 Diquat 2764-72-9 Oral Noncancer Minimal lens opacity and cataracts n/a RfD 2.2 x 10 -3 mg/kg-day
316 Disulfoton 298-04-4 Oral Noncancer ChE inhibition, optic nerve degeneration n/a RfD 4 x 10 -5 mg/kg-day
317 1,4-Dithiane 505-29-3 Oral Noncancer Nasal olfactory lesions n/a RfD 1 x 10 -2 mg/kg-day
318 Diuron 330-54-1 Oral Noncancer Abnormal pigments in blood n/a RfD 2 x 10 -3 mg/kg-day
319 Dodine 2439-10-3 Oral Noncancer Thyroid toxicity n/a RfD 4 x 10 -3 mg/kg-day
320 Endosulfan 115-29-7 Oral Noncancer Reduced body weight gain in males and females increased incidence of marked progressive glomerulonephrosis and blood vessel aneurysms in males n/a RfD 6 x 10 -3 mg/kg-day
321 Endothall 145-73-3 Oral Noncancer Increased absolute and relative weights of stomach and small intestine n/a RfD 2 x 10 -2 mg/kg-day
322 Endrin 72-20-8 Oral Noncancer Mild histological lesions in liver, occasional convulsions n/a RfD 3 x 10 -4 mg/kg-day
323 Epichlorohydrin 106-89-8 Oral Cancer Papillomas and carcinomas of the forestomach B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 9.9 x 10 -3 per mg/kg-day
324 Epichlorohydrin 106-89-8 Inhalation Cancer Nasal cavity tumors B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 1.2 x 10 -6 per µg/m3
325 Epichlorohydrin 106-89-8 Inhalation Noncancer Changes in the nasal turbinates n/a RfC 1 x 10 -3 mg/m3
326 1,2-Epoxybutane (EBU) 106-88-7 Inhalation Noncancer Degenerative lesions of the nasal cavity n/a RfC 2 x 10 -2 mg/m3
327 Ethephon 16672-87-0 Oral Noncancer Plasma ChE inhibition n/a RfD 5 x 10 -3 mg/kg-day
328 Ethion 563-12-2 Oral Noncancer Plasma cholinesterase inhibition n/a RfD 5 x 10 -4 mg/kg-day
329 2-Ethoxyethanol 110-80-5 Inhalation Noncancer Decreased testis weight, seminiferous tubule degeneration and decreased hemoglobin n/a RfC 2 x 10 -1 mg/m3
330 Ethyl Tertiary Butyl Ether (ETBE) 637-92-3 Inhalation Noncancer Increased absolute kidney weight in female rats n/a RfC 4 x 10 1 mg/m3
331 Ethyl Tertiary Butyl Ether (ETBE) 637-92-3 Inhalation Cancer Hepatocellular adenomas and carcinomas Suggestive evidence of carcinogenic potential (2005 guidelines)
Inhalation Unit Risk 8 x 10 -5 per mg/m3
332 Ethyl Tertiary Butyl Ether (ETBE) 637-92-3 Oral Noncancer Increased absolute kidney weight in female rats n/a RfD 1 mg/kg-day
333 Ethyl acetate 141-78-6 Oral Noncancer Mortality and body weight loss n/a RfD 9 x 10 -1 mg/kg-day
334 Ethyl chloride 75-00-3 Inhalation Noncancer Delayed fetal ossification n/a RfC 1 x 10 1 mg/m3
335 S-Ethyl dipropylthiocarbamate (EPTC) 759-94-4 Oral Noncancer Degenerative cardiomyopathy n/a RfD 2.5 x 10 -2 mg/kg-day
336 Ethyl ether 60-29-7 Oral Noncancer Depressed body weights n/a RfD 2 x 10 -1 mg/kg-day
337 Ethyl p-nitrophenyl phenylphosphorothioate (EPN) 2104-64-5 Oral Noncancer Neurotoxicity n/a RfD 1 x 10 -5 mg/kg-day
338 Ethylbenzene 100-41-4 Oral Noncancer Liver and kidney toxicity n/a RfD 1 x 10 -1 mg/kg-day
339 Ethylbenzene 100-41-4 Inhalation Noncancer Developmental toxicity n/a RfC 1 mg/m3
340 Ethylene diamine 107-15-3 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
341 Ethylene glycol 107-21-1 Oral Noncancer Kidney toxicity n/a RfD 2 mg/kg-day
342 Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) 111-76-2 Oral Noncancer Hemosiderin deposition in the liver n/a RfD 1 x 10 -1 mg/kg-day
343 Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) 111-76-2 Inhalation Noncancer Hemosiderin deposition in the liver n/a RfC 1.6 mg/m3
344 Ethylene oxide 75-21-8 Inhalation Cancer Lymphoid cancer, (female) breast cancer Carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 5 x 10 -3 per µg/m3
345 Ethylene thiourea (ETU) 96-45-7 Oral Noncancer Increased incidence of thyroid hyperplasia n/a RfD 8 x 10 -5 mg/kg-day
346 Ethylphthalyl ethylglycolate (EPEG) 84-72-0 Oral Noncancer Kidney damage and reduced lifespan n/a RfD 3 mg/kg-day
347 Express 101200-48-0 Oral Noncancer Elevated serum bilirubin and AST levels, increased urinary volume n/a RfD 8 x 10 -3 mg/kg-day
348 Fenamiphos 22224-92-6 Oral Noncancer ChE inhibition n/a RfD 2.5 x 10 -4 mg/kg-day
349 Fluometuron 2164-17-2 Oral Noncancer No adverse effects n/a RfD 1.3 x 10 -2 mg/kg-day
350 Fluoranthene 206-44-0 Oral Noncancer Nephropathy, increased liver weights, hematological alterations, and clinical effects n/a RfD 4 x 10 -2 mg/kg-day
351 Fluorene 86-73-7 Oral Noncancer Decreased RBC, packed cell volume and hemoglobin n/a RfD 4 x 10 -2 mg/kg-day
352 Fluorine (soluble fluoride) 7782-41-4 Oral Noncancer Objectionable dental fluorosis, a cosmetic effect n/a RfD 6 x 10 -2 mg/kg-day
353 Fluridone 59756-60-4 Oral Noncancer Glomerulonephritis, atrophic testes, eye keratitis decreased body weight and organ weights n/a RfD 8 x 10 -2 mg/kg-day
354 Flurprimidol 56425-91-3 Oral Noncancer Increased incidence of hepatocellular changes including fatty change and vacuolation (M) increased susceptibility to stress factors (F) n/a RfD 2 x 10 -2 mg/kg-day
355 Flutolanil 66332-96-5 Oral Noncancer Decreased body weight and body weight gains in both doses increased liver weights at high dose n/a RfD 6 x 10 -2 mg/kg-day
356 Fluvalinate 69409-94-5 Oral Noncancer Decreases in body weight gain increase in plantar ulcer (females) n/a RfD 1 x 10 -2 mg/kg-day
357 Folpet 133-07-3 Oral Noncancer Decreased body weight gain, altered serum chemistry parameters (decreased serum cholesterol, total protein, and serum albumin and globulin levels) n/a RfD 1 x 10 -1 mg/kg-day
358 Fonofos 944-22-9 Oral Noncancer Cholinesterase inhibition, cholinergic symptoms, and increased liver weight n/a RfD 2 x 10 -3 mg/kg-day
359 Formaldehyde 50-00-0 Inhalation Cancer Nasopharyngeal cancer, sinonasal cancer, myeloid leukemia Carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 1.1 x 10 -5 per µg/m3
360 Formaldehyde 50-00-0 Inhalation Noncancer Decreased pulmonary function, prevalence of current asthma or degree of asthma control, and allergic conditions in children (See Note) n/a RfC 7 x 10 -3 mg/m3
361 Formaldehyde 50-00-0 Oral Noncancer Reduced weight gain, histopathology in rats n/a RfD 2 x 10 -1 mg/kg-day
362 Fosetyl-al 39148-24-8 Oral Noncancer Slight testicular degeneration n/a RfD 3 mg/kg-day
363 Furan 110-00-9 Oral Noncancer Hepatic lesions n/a RfD 1 x 10 -3 mg/kg-day
364 Furfural 98-01-1 Oral Noncancer Mild hepatocellular vacuolization n/a RfD 3 x 10 -3 mg/kg-day
365 Furmecyclox 60568-05-0 Oral Cancer Combined liver nodules and carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 3 x 10 -2 per mg/kg-day
366 Glufosinate-ammonium 77182-82-2 Oral Noncancer Increased absolute and relative kidney weights in males n/a RfD 4 x 10 -4 mg/kg-day
367 Glycidaldehyde 765-34-4 Oral Noncancer Weight gain retardation, enlarged adrenals, hydropic renal pelvis and hematopoietic effects n/a RfD 4 x 10 -4 mg/kg-day
368 Glyphosate 1071-83-6 Oral Noncancer Increased incidence of renal tubular dilation in F3b offspring n/a RfD 1 x 10 -1 mg/kg-day
369 Haloxyfop-methyl 69806-40-2 Oral Noncancer Reduced relative kidney weights in F0, F1, and F2b adults; reduced fertility in the F1/F2b generation n/a RfD 5 x 10 -5 mg/kg-day
370 Harmony 79277-27-3 Oral Noncancer Reduced body weight gains in males, reduced serum sodium in males and females n/a RfD 1.3 x 10 -2 mg/kg-day
371 Heptachlor 76-44-8 Oral Cancer Hepatocellular carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 4.5 per mg/kg-day
372 Heptachlor 76-44-8 Inhalation Cancer Hepatocellular carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 1.3 x 10 -3 per µg/m3
373 Heptachlor 76-44-8 Oral Noncancer Liver weight increases in males n/a RfD 5 x 10 -4 mg/kg-day
374 Heptachlor epoxide 1024-57-3 Oral Noncancer Increased liver-to-body weight ratio in both males and females n/a RfD 1.3 x 10 -5 mg/kg-day
375 Heptachlor epoxide 1024-57-3 Oral Cancer Hepatocellular carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 9.1 per mg/kg-day
376 Heptachlor epoxide 1024-57-3 Inhalation Cancer Hepatocellular carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 2.6 x 10 -3 per µg/m3
377 n-Heptane 142-82-5 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
378 Hexabromobenzene 87-82-1 Oral Noncancer Induced serum carboxylesterase activity, increased relative liver weight, increased liver porphyrins n/a RfD 2 x 10 -3 mg/kg-day
379 Hexabromodiphenyl ether 36483-60-0 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
380 2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153) 68631-49-2 Oral Noncancer Neurobehavioral effects n/a RfD 2 x 10 -4 mg/kg-day
381 Hexachlorobenzene 118-74-1 Oral Cancer Hepatocellular carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.6 per mg/kg-day
382 Hexachlorobenzene 118-74-1 Inhalation Cancer Hepatocellular carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 4.6 x 10 -4 per µg/m3
383 Hexachlorobenzene 118-74-1 Oral Noncancer Liver effects n/a RfD 8 x 10 -4 mg/kg-day
384 Hexachlorobutadiene 87-68-3 Inhalation Cancer Renal tubular adenomas and adenocarcinomas C (Possible human carcinogen) (1986 guidelines)
Inhalation Unit Risk 2.2 x 10 -5 per µg/m3
385 Hexachlorobutadiene 87-68-3 Oral Cancer Renal tubular adenomas and adenocarcinomas C (Possible human carcinogen) (1986 guidelines)
Oral Slope Factor 7.8 x 10 -2 per mg/kg-day
386 alpha-Hexachlorocyclohexane (alpha-HCH) 319-84-6 Oral Cancer Hepatic nodules and hepatocellular carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 6.3 per mg/kg-day
387 alpha-Hexachlorocyclohexane (alpha-HCH) 319-84-6 Inhalation Cancer Hepatic nodules and hepatocellular carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 1.8 x 10 -3 per µg/m3
388 beta-Hexachlorocyclohexane (beta-HCH) 319-85-7 Oral Cancer Hepatic nodules and hepatocellular carcinomas C (Possible human carcinogen) (1986 guidelines)
Oral Slope Factor 1.8 per mg/kg-day
389 beta-Hexachlorocyclohexane (beta-HCH) 319-85-7 Inhalation Cancer Hepatic nodules and hepatocellular carcinomas C (Possible human carcinogen) (1986 guidelines)
Inhalation Unit Risk 5.3 x 10 -4 per µg/m3
390 delta-Hexachlorocyclohexane (delta-HCH) 319-86-8 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
391 epsilon-Hexachlorocyclohexane (epsilon-HC) 6108-10-7 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
392 gamma-Hexachlorocyclohexane (gamma-HCH) 58-89-9 Oral Noncancer Liver and kidney toxicity n/a RfD 3 x 10 -4 mg/kg-day
393 technical Hexachlorocyclohexane (t-HCH) 608-73-1 Oral Cancer Liver nodules and hepatocellular carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.8 per mg/kg-day
394 technical Hexachlorocyclohexane (t-HCH) 608-73-1 Inhalation Cancer Liver nodules and hepatocellular carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 5.1 x 10 -4 per µg/m3
395 Hexachlorocyclopentadiene (HCCPD) 77-47-4 Oral Noncancer Chronic irritation n/a RfD 6 x 10 -3 mg/kg-day
396 Hexachlorocyclopentadiene (HCCPD) 77-47-4 Inhalation Noncancer Suppurative inflammation of the nose n/a RfC 2 x 10 -4 mg/m3
397 Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD 57653-85-7 Inhalation Cancer Liver tumors (adenomas and carcinomas; neoplastic nodules and hepatocellular carcinomas) B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 1.3 per µg/m3
398 Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD 57653-85-7 Oral Cancer Liver tumors (adenomas and carcinomas; neoplastic nodules and hepatocellular carcinomas) B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 6.2 x 10 3 per mg/kg-day
399 Hexachloroethane 67-72-1 Oral Noncancer Atrophy and degeneration of renal tubules n/a RfD 7 x 10 -4 mg/kg-day
400 Hexachloroethane 67-72-1 Oral Cancer Renal adenomas and carcinomas (combined) Likely to be carcinogenic to humans (2005 guidelines)
Oral Slope Factor 4 x 10 -2 per mg/kg-day
401 Hexachloroethane 67-72-1 Inhalation Noncancer Neurotoxicity (tremors and ruffled pelt) n/a RfC 3 x 10 -2 mg/m3
402 Hexachlorophene 70-30-4 Oral Noncancer Swollen salivary glands, status spongiosis in brain and optic nerve n/a RfD 3 x 10 -4 mg/kg-day
403 Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) 121-82-4 Oral Cancer Liver (hepatocellular adenomas or carcinomas) and lung (alveolar/bronchiolar adenomas or carcinomas) Suggestive evidence of carcinogenic potential (2005 guidelines)
Oral Slope Factor 8 x 10 -2 per mg/kg-day
404 Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) 121-82-4 Oral Noncancer Kidney medullary papillary necrosis in F344 rats n/a RfD 1 x 10 -2 mg/kg-day
405 Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) 121-82-4 Oral Noncancer Suppurative prostatitis in F344 rats n/a RfD 8 x 10 -4 mg/kg-day
406 Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) 121-82-4 Oral Noncancer Convulsions in F344 rats n/a RfD 4 x 10 -3 mg/kg-day
407 1,6-Hexamethylene diisocyanate 822-06-0 Inhalation Noncancer Degeneration of olfactory epithelium n/a RfC 1 x 10 -5 mg/m3
408 n-Hexane 110-54-3 Inhalation Noncancer Peripheral neuropathy (decreased MCV at 12 weeks) n/a RfC 7 x 10 -1 mg/m3
409 2-Hexanone 591-78-6 Inhalation Noncancer Motor conduction velocity of the sciatic-tibial nerve n/a RfC 3 x 10 -2 mg/m3
410 2-Hexanone 591-78-6 Oral Noncancer Axonal swelling of the peripheral nerve n/a RfD 5 x 10 -3 mg/kg-day
411 Hexazinone 51235-04-2 Oral Noncancer Decreased body weight n/a RfD 3.3 x 10 -2 mg/kg-day
412 Hydrazine/Hydrazine sulfate 302-01-2 Inhalation Cancer Nasal cavity adenoma or adenocarcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 4.9 x 10 -3 per µg/m3
413 Hydrazine/Hydrazine sulfate 302-01-2 Oral Cancer Hepatoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 3 per mg/kg-day
414 Hydrogen Cyanide and Cyanide Salts Various Oral Noncancer Decreased cauda epididymis weight in male F344/N rats n/a RfD 6 x 10 -4 mg/kg-day
415 Hydrogen Cyanide and Cyanide Salts Various Inhalation Noncancer Thyroid enlargement and altered iodide uptake n/a RfC 8 x 10 -4 mg/m3
416 Hydrogen chloride 7647-01-0 Inhalation Noncancer Hyperplasia of nasal mucosa larynx and trachea n/a RfC 2 x 10 -2 mg/m3
417 Hydrogen sulfide 7783-06-4 Inhalation Noncancer Nasal lesions of the olfactory mucosa n/a RfC 2 x 10 -3 mg/m3
418 Imazalil 35554-44-0 Oral Noncancer Decreased body weight gain n/a RfD 1.3 x 10 -2 mg/kg-day
419 Imazaquin 81335-37-7 Oral Noncancer Decreased body weight gain, skeletal myopathy, slight anemia, bone marrow hyperplasia, elevated serum SGOT, SGPT, CPK n/a RfD 2.5 x 10 -1 mg/kg-day
420 Indeno[1,2,3-cd]pyrene 193-39-5 None Cancer None B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
NA 0 NA
421 Iprodione 36734-19-7 Oral Noncancer Increased RBC Heinz bodies; decreased prostate weight n/a RfD 4 x 10 -2 mg/kg-day
422 Isobutyl alcohol 78-83-1 Oral Noncancer Hypoactivity and ataxia n/a RfD 3 x 10 -1 mg/kg-day
423 Isophorone 78-59-1 Oral Noncancer Kidney pathology n/a RfD 2 x 10 -1 mg/kg-day
424 Isophorone 78-59-1 Oral Cancer Preputial gland carcinoma C (Possible human carcinogen) (1986 guidelines)
Oral Slope Factor 9.5 x 10 -4 per mg/kg-day
425 Isopropalin 33820-53-0 Oral Noncancer Reduced hemoglobin concentration, lowered hematocrits, and altered organ weights n/a RfD 1.5 x 10 -2 mg/kg-day
426 Isopropyl methyl phosphonic acid (IMPA) 1832-54-8 Oral Noncancer No adverse effects observed n/a RfD 1 x 10 -1 mg/kg-day
427 Isoxaben 82558-50-7 Oral Noncancer Increased BUN; decreased serum AP and AST; decreased food consumption efficiency; increased heart/body weight n/a RfD 5 x 10 -2 mg/kg-day
428 Lactofen 77501-63-4 Oral Noncancer Increased absolute and relative liver weight; hepatocytomegaly in males n/a RfD 2 x 10 -3 mg/kg-day
429 Lead and compounds (inorganic) 7439-92-1 None Cancer None B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
NA 0 NA
430 Libby Amphibole Asbestos 1318-09-8 Inhalation Noncancer Localized pleural thickening n/a RfC 9 x 10 -5 fiber/cc
431 Libby Amphibole Asbestos 1318-09-8 Inhalation Cancer Cancer mortality from lung cancer and mesothelioma Carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 1.7 x 10 -1 per fiber/cc
432 Linuron 330-55-2 Oral Noncancer Abnormal blood pigment n/a RfD 2 x 10 -3 mg/kg-day
433 Londax 83055-99-6 Oral Noncancer Liver effects n/a RfD 2 x 10 -1 mg/kg-day
434 Malathion 121-75-5 Oral Noncancer RBC ChE depression n/a RfD 2 x 10 -2 mg/kg-day
435 Maleic anhydride 108-31-6 Oral Noncancer Renal lesions n/a RfD 1 x 10 -1 mg/kg-day
436 Maleic hydrazide 123-33-1 Oral Noncancer Renal dysfunction n/a RfD 5 x 10 -1 mg/kg-day
437 Maneb 12427-38-2 Oral Noncancer Increased thyroid weight n/a RfD 5 x 10 -3 mg/kg-day
438 Manganese 7439-96-5 Inhalation Noncancer Impairment of neurobehavioral function n/a RfC 5 x 10 -5 mg/m3
439 Manganese 7439-96-5 Oral Noncancer CNS effects n/a RfD 1.4 x 10 -1 mg/kg-day
440 Mepiquat chloride 24307-26-4 Oral Noncancer Sedation and tonoclonic spasms decreased food intake and body weights hematologic effects n/a RfD 3 x 10 -2 mg/kg-day
441 Mercuric chloride (HgCl2) 7487-94-7 Oral Noncancer Autoimmune effects (autoimmune glomerulonephritis) n/a RfD 3 x 10 -4 mg/kg-day
442 Mercury, elemental 7439-97-6 Inhalation Noncancer Hand tremor; increases in memory disturbances; slight subjective and objective evidence of autonomic dysfunction n/a RfC 3 x 10 -4 mg/m3
443 Merphos 150-50-5 Oral Noncancer Ataxia, delayed neurotoxicity and weight loss n/a RfD 3 x 10 -5 mg/kg-day
444 Merphos oxide 78-48-8 Oral Noncancer Ataxia, delayed neurotoxicity and weight loss n/a RfD 3 x 10 -5 mg/kg-day
445 Metalaxyl 57837-19-1 Oral Noncancer Increased serum alkaline phosphatase levels and increased liver-to-brain weight ratio n/a RfD 6 x 10 -2 mg/kg-day
446 Methacrylonitrile 126-98-7 Oral Noncancer Increased SGOT and SGPT levels n/a RfD 1 x 10 -4 mg/kg-day
447 Methamidophos 10265-92-6 Oral Noncancer ChE inhibition n/a RfD 5 x 10 -5 mg/kg-day
448 Methanol 67-56-1 Oral Noncancer Extra cervical ribs n/a RfD 2 mg/kg-day
449 Methanol 67-56-1 Inhalation Noncancer Reduced brain weight in rat pups at 6 weeks of age n/a RfC 2 x 10 1 mg/m3
450 Methidathion 950-37-8 Oral Noncancer Liver toxicity n/a RfD 1 x 10 -3 mg/kg-day
451 Methomyl 16752-77-5 Oral Noncancer Kidney and spleen pathology n/a RfD 2.5 x 10 -2 mg/kg-day
452 Methoxychlor 72-43-5 Oral Noncancer Excessive loss of litters n/a RfD 5 x 10 -3 mg/kg-day
453 2-Methoxyethanol 109-86-4 Inhalation Noncancer Testicular effects n/a RfC 2 x 10 -2 mg/m3
454 Methyl acrylate 96-33-3 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
455 Methyl chloride 74-87-3 Inhalation Noncancer Cerebellar lesions n/a RfC 9 x 10 -2 mg/m3
456 Methyl ethyl ketone (MEK) 78-93-3 Inhalation Noncancer Developmental toxicity (skeletal variations) n/a RfC 5 mg/m3
457 Methyl ethyl ketone (MEK) 78-93-3 Oral Noncancer Decreased pup body weight n/a RfD 6 x 10 -1 mg/kg-day
458 Methyl isobutyl ketone (MIBK) 108-10-1 Inhalation Noncancer Reduced fetal body weight, skeletal variations, and increased fetal death in mice, and skeletal variations in rats. n/a RfC 3 mg/m3
459 Methyl methacrylate 80-62-6 Inhalation Noncancer Degeneration/ atrophy of olfactory epithelium (male rats) n/a RfC 7 x 10 -1 mg/m3
460 Methyl methacrylate 80-62-6 Oral Noncancer None n/a RfD 1.4 mg/kg-day
461 Methyl parathion 298-00-0 Oral Noncancer RBC, ChE inhibition; reduced hemoglobin, hematocrit and RBCs n/a RfD 2.5 x 10 -4 mg/kg-day
462 Methyl tert-butyl ether (MTBE) 1634-04-4 Inhalation Noncancer Increased absolute and relative liver and kidney weights and increased severity of spontaneous renal lesions (females), increased prostration (females), and swollen periocular tissue (males and females) n/a RfC 3 mg/m3
463 4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) 94-81-5 Oral Noncancer Male reproductive toxicity and other effects (including decreased body weight gain), increased liver and kidney weights n/a RfD 1 x 10 -2 mg/kg-day
464 2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) 93-65-2 Oral Noncancer Increased absolute and relative kidney weights n/a RfD 1 x 10 -3 mg/kg-day
465 2-Methyl-4-chlorophenoxyacetic acid (MCPA) 94-74-6 Oral Noncancer Kidney and liver toxicity n/a RfD 5 x 10 -4 mg/kg-day
466 Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) 101-68-8 Inhalation Noncancer Hyperplasia of olfactory epithelium n/a RfC 6 x 10 -4 mg/m3
467 4,4'-Methylene bis(N,N'-dimethyl)aniline 101-61-1 Oral Cancer Thyroid, follicular cell carcinoma/ adenoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 4.6 x 10 -2 per mg/kg-day
468 Methylmercury (MeHg) 22967-92-6 Oral Noncancer Developmental neuropsychological impairment n/a RfD 1 x 10 -4 mg/kg-day
469 Methylmercury (MeHg) 22967-92-6 Oral Noncancer Developmental neuropsychological impairment n/a RfD 1 x 10 -4 mg/kg-day
470 2-Methylnaphthalene 91-57-6 Oral Noncancer Pulmonary alveolar proteinosis n/a RfD 4 x 10 -3 mg/kg-day
471 2-Methylphenol 95-48-7 Oral Noncancer Decreased body weights and neurotoxicity n/a RfD 5 x 10 -2 mg/kg-day
472 3-Methylphenol 108-39-4 Oral Noncancer Decreased body weights and neurotoxicity n/a RfD 5 x 10 -2 mg/kg-day
473 4-Methylphenol 106-44-5 None Cancer None C (Possible human carcinogen) (1986 guidelines)
NA 0 NA
474 Metolachlor 51218-45-2 Oral Noncancer Decreased body weight gain, decreased pup weight and parental food consumption n/a RfD 1.5 x 10 -1 mg/kg-day
475 Metribuzin 21087-64-9 Oral Noncancer Liver and kidney effects, decreased body weight, mortality n/a RfD 2.5 x 10 -2 mg/kg-day
476 Mirex 2385-85-5 Oral Noncancer Liver cytomegaly, fatty metamorphosis, angiectasis; thyroid cystic follicles n/a RfD 2 x 10 -4 mg/kg-day
477 Molinate 2212-67-1 Oral Noncancer Reproductive toxicity n/a RfD 2 x 10 -3 mg/kg-day
478 Molybdenum 7439-98-7 Oral Noncancer Increased uric acid levels n/a RfD 5 x 10 -3 mg/kg-day
479 Monochloramine 10599-90-3 Oral Noncancer No observed effects n/a RfD 1 x 10 -1 mg/kg-day
480 Naled 300-76-5 Oral Noncancer Brain ChE inhibition n/a RfD 2 x 10 -3 mg/kg-day
481 Naphthalene 91-20-3 Inhalation Noncancer Nasal effects: hyperplasia and metaplasia in respiratory and olfactory epithelium, respectively n/a RfC 3 x 10 -3 mg/m3
482 Naphthalene 91-20-3 Oral Noncancer Decreased mean terminal body weight in males n/a RfD 2 x 10 -2 mg/kg-day
483 Napropamide 15299-99-7 Oral Noncancer Decreased body weight gain in parental animals and pups n/a RfD 1 x 10 -1 mg/kg-day
484 Nickel carbonyl 13463-39-3 None Cancer None B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
NA 0 NA
485 Nickel refinery dust None Inhalation Cancer Lung cancer A (Human carcinogen) (1986 guidelines)
Inhalation Unit Risk 2.4 x 10 -4 per µg/m3
486 Nickel subsulfide 12035-72-2 Inhalation Cancer Lung cancer A (Human carcinogen) (1986 guidelines)
Inhalation Unit Risk 4.8 x 10 -4 per µg/m3
487 Nickel, soluble salts Various Oral Noncancer Decreased body and organ weights n/a RfD 2 x 10 -2 mg/kg-day
488 Nitrate 14797-55-8 Oral Noncancer Early clinical signs of methemoglobinemia in excess of 10% (0-3 months old infants formula) n/a RfD 1.6 mg/kg-day
489 Nitrite 14797-65-0 Oral Noncancer Methemoglobinemia n/a RfD 1 x 10 -1 mg/kg-day
490 Nitrobenzene 98-95-3 Oral Noncancer Increased methemoglobin levels n/a RfD 2 x 10 -3 mg/kg-day
491 Nitrobenzene 98-95-3 Inhalation Noncancer Bronchiolization of the alveoli and olfactory degeneration n/a RfC 9 x 10 -3 mg/m3
492 Nitrobenzene 98-95-3 Inhalation Cancer Liver hepatocellular adenomas or carcinomas, kidney tubular adenomas or carcinomas, thyroid follicular cell adenomas or carcinomas Likely to be carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 4 x 10 -5 per µg/m3
493 Nitroguanidine 556-88-7 Oral Noncancer Reduced weight gain in female rats, maternal/ fetal toxicity in rats, and equivocal evidence of developmental toxicity in rabbits n/a RfD 1 x 10 -1 mg/kg-day
494 2-Nitropropane 79-46-9 Inhalation Noncancer Liver focal vacuolization and nodules n/a RfC 2 x 10 -2 mg/m3
495 N-Nitroso-N-methylethylamine 10595-95-6 Oral Cancer Hepatocellular carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 2.2 x 10 1 per mg/kg-day
496 N-Nitroso-di-n-butylamine 924-16-3 Inhalation Cancer Bladder and esophagus tumors B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 1.6 x 10 -3 per µg/m3
497 N-Nitroso-di-n-butylamine 924-16-3 Oral Cancer Bladder and esophagus tumors B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 5.4 per mg/kg-day
498 N-Nitrosodi-N-propylamine 621-64-7 Oral Cancer Hepatocellular carcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 7 per mg/kg-day
499 N-Nitrosodiethanolamine 1116-54-7 Oral Cancer Hepatocellular carcinoma, cholangiocellular carcinoma and adenoma and neoplastic nodules B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 2.8 per mg/kg-day
500 N-Nitrosodiethylamine 55-18-5 Inhalation Cancer Liver tumors B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 4.3 x 10 -2 per µg/m3
501 N-Nitrosodiethylamine 55-18-5 Oral Cancer Liver tumors B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.5 x 10 2 per mg/kg-day
502 N-Nitrosodimethylamine 62-75-9 Inhalation Cancer Liver tumors B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 1.4 x 10 -2 per µg/m3
503 N-Nitrosodimethylamine 62-75-9 Oral Cancer Liver tumors B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 5.1 x 10 1 per mg/kg-day
504 N-Nitrosodiphenylamine 86-30-6 Oral Cancer Transitional cell carcinoma of the bladder B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 4.9 x 10 -3 per mg/kg-day
505 N-Nitrosopyrrolidine 930-55-2 Inhalation Cancer Hepatocellular carcinoma and adenoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 6.1 x 10 -4 per µg/m3
506 N-Nitrosopyrrolidine 930-55-2 Oral Cancer Hepatocellular carcinoma and adenoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 2.1 per mg/kg-day
507 Nonabromodiphenyl ether 63936-56-1 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
508 Norflurazon 27314-13-2 Oral Noncancer Liver and thyroid effects n/a RfD 4 x 10 -2 mg/kg-day
509 NuStar 85509-19-9 Oral Noncancer Liver cell enlargement n/a RfD 7 x 10 -4 mg/kg-day
510 Octabromodiphenyl ether 32536-52-0 Oral Noncancer Induction of hepatic enzymes; liver histopathology n/a RfD 3 x 10 -3 mg/kg-day
511 Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX) 2691-41-0 Oral Noncancer Hepatic lesions n/a RfD 5 x 10 -2 mg/kg-day
512 Oryzalin 19044-88-3 Oral Noncancer Increases in serum cholesterol, alkaline phosphatase, and relative liver and kidney weights, and decreases in alanine transaminase and adrenal weights n/a RfD 5 x 10 -2 mg/kg-day
513 Oxadiazon 19666-30-9 Oral Noncancer Increased levels of serum proteins and increased liver weights n/a RfD 5 x 10 -3 mg/kg-day
514 Oxamyl 23135-22-0 Oral Noncancer Decreased body weight gain and food consumption n/a RfD 2.5 x 10 -2 mg/kg-day
515 Oxyfluorfen 42874-03-3 Oral Noncancer Increased absolute liver weight and nonneoplastic lesions n/a RfD 3 x 10 -3 mg/kg-day
516 Paclobutrazol 76738-62-0 Oral Noncancer Elevated liver weights, serum cholesterol, hepatic aminopyrine N-demethylase activity, and alanine transaminase levels n/a RfD 1.3 x 10 -2 mg/kg-day
517 Paraquat 1910-42-5 Oral Noncancer Chronic pneumonitis n/a RfD 4.5 x 10 -3 mg/kg-day
518 Parathion 56-38-2 None Cancer None C (Possible human carcinogen) (1986 guidelines)
NA 0 NA
519 Pendimethalin 40487-42-1 Oral Noncancer Increase in serum alkaline phosphatase and liver weight, and hepatic lesions n/a RfD 4 x 10 -2 mg/kg-day
520 Pentabromodiphenyl ether 32534-81-9 Oral Noncancer Induction of hepatic enzymes n/a RfD 2 x 10 -3 mg/kg-day
521 2,2',4,4',5-Pentabromodiphenyl ether (BDE-99) 60348-60-9 Oral Noncancer Neurobehavioral effects n/a RfD 1 x 10 -4 mg/kg-day
522 Pentachlorobenzene 608-93-5 Oral Noncancer Liver and kidney toxicity n/a RfD 8 x 10 -4 mg/kg-day
523 Pentachlorocyclopentadiene 25329-35-5 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
524 Pentachloronitrobenzene (PCNB) 82-68-8 Oral Noncancer Liver toxicity n/a RfD 3 x 10 -3 mg/kg-day
525 Pentachlorophenol 87-86-5 Oral Noncancer Hepatotoxicity n/a RfD 5 x 10 -3 mg/kg-day
526 Pentachlorophenol 87-86-5 Oral Cancer Hepatocellular adenomas or carcinomas and adrenal benign or malignant pheochromocytomas Likely to be carcinogenic to humans (2005 guidelines)
Oral Slope Factor 4 x 10 -1 per mg/kg-day
527 Perchlorate (ClO4) and Perchlorate Salts 7790-98-9 Oral Noncancer Radioactive iodide uptake inhibition (RAIU) in the thyroid n/a RfD 7 x 10 -4 mg/kg-day
528 Perfluorobutanoic Acid (PFBA) 375-22-4 Oral Noncancer Decreased total T4 n/a RfD 1 x 10 -2 mg/kg-day
529 Perfluorobutanoic Acid (PFBA) 375-22-4 Oral Noncancer Developmental delays n/a RfD 6 x 10 -3 mg/kg-day
530 Perfluorobutanoic Acid (PFBA) 375-22-4 Oral Noncancer Increased hepatocellular hypertrophy n/a RfD 1 x 10 -2 mg/kg-day
531 Perfluorobutanoic Acid (PFBA) 375-22-4 Oral Noncancer Developmental delays n/a RfD 6 x 10 -3 mg/kg-day
532 Perfluorobutanoic Acid (PFBA) 375-22-4 Oral Noncancer Increased hepatocellular hypertrophy n/a RfD 1 x 10 -3 mg/kg-day
533 Perfluorobutanoic Acid (PFBA) 375-22-4 Oral Noncancer Developmental delays n/a RfD 6 x 10 -3 mg/kg-day
534 Perfluorobutanoic Acid (PFBA) 375-22-4 Oral Noncancer Increased hepatocellular hypertrophy (Liver), Decreased total T4 (Thyroid) n/a RfD 1 x 10 -3 mg/kg-day
535 Perfluorodecanoic Acid (PFDA) 335-76-2 Oral Noncancer Decreased serum antibody concentrations for both tetanus and diphtheria in children at age 7 yr and PFDA measured at age 5 yr n/a RfD 2 x 10 -9 mg/kg-day
536 Perfluorodecanoic Acid (PFDA) 335-76-2 Oral Noncancer Decreased birth weight in male and female children. n/a RfD 2 x 10 -9 mg/kg-day
537 Perfluorodecanoic Acid (PFDA) 335-76-2 Oral Noncancer Decreased birth weight in male and female children. n/a RfD 2 x 10 -9 mg/kg-day
538 Perfluorodecanoic Acid (PFDA) 335-76-2 Oral Noncancer Increased relative Liver weight in SD female rats n/a RfD 6 x 10 -7 mg/kg-day
539 Perfluorodecanoic Acid (PFDA) 335-76-2 Oral Noncancer Decreased absolute whole epididymis weight in SD rats (Male Reproductive). n/a RfD 3 x 10 -6 mg/kg-day
540 Perfluorodecanoic Acid (PFDA) 335-76-2 Oral Noncancer Decreased serum antibody concentrations for tetanus and diphtheria in children at age 7 yr and PFDA measured at age 5 yr. n/a RfD 2 x 10 -9 mg/kg-day
541 Perfluorodecanoic Acid (PFDA) 335-76-2 Oral Noncancer Increased number of days spent in diestrus in SD rats (Female Reproductive). n/a RfD 1 x 10 -6 mg/kg-day
542 Perfluorohexanoic Acid (PFHxA) 307-24-4 Oral Noncancer Decreased total T4 in adult male Harlan Sprague-Dawley rats n/a RfD 1 x 10 -3 mg/kg-day
543 Perfluorohexanoic Acid (PFHxA) 307-24-4 Oral Noncancer Decreased red blood cells in adult female Crl:CD Sprague‑Dawley rats n/a RfD 8 x 10 -4 mg/kg-day
544 Perfluorohexanoic Acid (PFHxA) 307-24-4 Oral Noncancer Increased hepatocellular hypertrophy in adult rats n/a RfD 1 x 10 -3 mg/kg-day
545 Perfluorohexanoic Acid (PFHxA) 307-24-4 Oral Noncancer Decreased postnatal (PND 0) body weight in F1 Sprague‑Dawley male and female rats n/a RfD 5 x 10 -4 mg/kg-day
546 Perfluorohexanoic Acid (PFHxA) 307-24-4 Oral Noncancer Decreased red blood cells in adult female Crl:CD Sprague‑Dawley rats n/a RfD 5 x 10 -3 mg/kg-day
547 Perfluorohexanoic Acid (PFHxA) 307-24-4 Oral Noncancer Increased hepatocellular hypertrophy in adult male Crl:CD Sprague‑Dawley rats n/a RfD 4 x 10 -4 mg/kg-day
548 Perfluorohexanoic Acid (PFHxA) 307-24-4 Oral Noncancer Decreased postnatal (PND 0) body weight in F1 Sprague‑Dawley male and female rats n/a RfD 5 x 10 -4 mg/kg-day
549 Permethrin 52645-53-1 Oral Noncancer Increased liver weights n/a RfD 5 x 10 -2 mg/kg-day
550 Phenanthrene 85-01-8 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
551 Phenmedipham 13684-63-4 Oral Noncancer No adverse effects n/a RfD 2.5 x 10 -1 mg/kg-day
552 Phenol 108-95-2 Oral Noncancer Decreased maternal weight gain n/a RfD 3 x 10 -1 mg/kg-day
553 m-Phenylenediamine 108-45-2 Oral Noncancer Increased relative and absolute liver weights and degenerative liver lesions n/a RfD 6 x 10 -3 mg/kg-day
554 Phenylmercuric acetate 62-38-4 Oral Noncancer Renal damage n/a RfD 8 x 10 -5 mg/kg-day
555 Phosgene 75-44-5 Inhalation Noncancer Collagen staining indicative of fibrosis n/a RfC 3 x 10 -4 mg/m3
556 Phosmet 732-11-6 Oral Noncancer Reduced body weight (males), liver cell vacuolation, cholinesterase inhibition n/a RfD 2 x 10 -2 mg/kg-day
557 Phosphine 7803-51-2 Oral Noncancer Body weight and clinical parameters n/a RfD 3 x 10 -4 mg/kg-day
558 Phosphine 7803-51-2 Inhalation Noncancer Decreased body weight n/a RfC 3 x 10 -4 mg/m3
559 Phosphoric acid 7664-38-2 Inhalation Noncancer Bronchiolar fibrosis n/a RfC 1 x 10 -2 mg/m3
560 Phthalic anhydride 85-44-9 Oral Noncancer Lung and kidney histopathology n/a RfD 2 mg/kg-day
561 Picloram 1918-02-1 Oral Noncancer Increased liver weights n/a RfD 7 x 10 -2 mg/kg-day
562 Pirimiphos-methyl 29232-93-7 Oral Noncancer Transient plasma ChE depression n/a RfD 1 x 10 -2 mg/kg-day
563 Polychlorinated Biphenyls (PCBs) 1336-36-3 Inhalation Cancer Liver hepatocellular adenomas, carcinomas, cholangiomas, or cholangiocarcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 1 x 10 -4 per µg/m3
564 Polychlorinated Biphenyls (PCBs) 1336-36-3 Oral Cancer Liver hepatocellular adenomas, carcinomas, cholangiomas, or cholangiocarcinomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 2 per mg/kg-day
565 Potassium cyanide 151-50-8 Oral Noncancer Decreased cauda epididymis weight in male F344/N rats. The RfD for potassium cyanide is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. n/a RfD 2 x 10 -3 mg/kg-day
566 Potassium silver cyanide 506-61-6 Oral Noncancer Decreased cauda epididymis weight in male F344/N rats. The RfD for potassium cyanide is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. n/a RfD 5 x 10 -3 mg/kg-day
567 Prochloraz 67747-09-5 Oral Cancer Liver adenoma/ carcinoma combined C (Possible human carcinogen) (1986 guidelines)
Oral Slope Factor 1.5 x 10 -1 per mg/kg-day
568 Prochloraz 67747-09-5 Oral Noncancer Increase in SAP and liver weights, liver histopathology n/a RfD 9 x 10 -3 mg/kg-day
569 Prometon 1610-18-0 Oral Noncancer No treatment related effects observed n/a RfD 1.5 x 10 -2 mg/kg-day
570 Prometryn 7287-19-6 Oral Noncancer Liver and kidney degeneration and bone marrow atrophy n/a RfD 4 x 10 -3 mg/kg-day
571 Pronamide 23950-58-5 Oral Noncancer No effects n/a RfD 7.5 x 10 -2 mg/kg-day
572 Propachlor 1918-16-7 Oral Noncancer Decreased weight gain, food consumption increased relative liver weights n/a RfD 1.3 x 10 -2 mg/kg-day
573 Propanil 709-98-8 Oral Noncancer Increased relative spleen weight in females n/a RfD 5 x 10 -3 mg/kg-day
574 Propargite 2312-35-8 Oral Noncancer Reduced body weight gain (maternal), increased resorption, reduced body weight (fetal), delayed ossification n/a RfD 2 x 10 -2 mg/kg-day
575 Propargyl alcohol 107-19-7 Oral Noncancer Renal and hepatotoxicity n/a RfD 2 x 10 -3 mg/kg-day
576 Propazine 139-40-2 Oral Noncancer Decrease in body weight n/a RfD 2 x 10 -2 mg/kg-day
577 Propham 122-42-9 Oral Noncancer Increase in male spleen weight and ChE depression in females n/a RfD 2 x 10 -2 mg/kg-day
578 Propiconazole 60207-90-1 Oral Noncancer Gastric mucosal irritation n/a RfD 1.3 x 10 -2 mg/kg-day
579 Propionaldehyde 123-38-6 Inhalation Noncancer Atrophy of olfactory epithelium n/a RfC 8 x 10 -3 mg/m3
580 Propylene glycol monomethyl ether (PGME) 107-98-2 Inhalation Noncancer Mild reversible sedation n/a RfC 2 mg/m3
581 Propylene oxide 75-56-9 Oral Cancer Forestomach, squamous cell carcinoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 2.4 x 10 -1 per mg/kg-day
582 Propylene oxide 75-56-9 Inhalation Noncancer Nest-like infolds of the nasal respiratory epithelium n/a RfC 3 x 10 -2 mg/m3
583 Propylene oxide 75-56-9 Inhalation Cancer Nasal cavity hemangioma or hemangiosarcoma B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 3.7 x 10 -6 per µg/m3
584 Pursuit 81335-77-5 Oral Noncancer Decreased packed cell volume, hemoglobin, erythrocytes in females n/a RfD 2.5 x 10 -1 mg/kg-day
585 Pydrin 51630-58-1 Oral Noncancer Neurological dysfunction n/a RfD 2.5 x 10 -2 mg/kg-day
586 Pyrene 129-00-0 Oral Noncancer Kidney effects (renal tubular pathology, decreased kidney weights) n/a RfD 3 x 10 -2 mg/kg-day
587 Pyridine 110-86-1 Oral Noncancer Increased liver weight n/a RfD 1 x 10 -3 mg/kg-day
588 Quinalphos 13593-03-8 Oral Noncancer No adverse effects reported n/a RfD 5 x 10 -4 mg/kg-day
589 Quinoline 91-22-5 Oral Cancer Hepatic hemangioendotheliomas or hemangiosarcomas B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 3 per mg/kg-day
590 Refractory ceramic fibers None None Cancer None B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
NA 0 NA
591 Resmethrin 10453-86-8 Oral Noncancer Reproductive toxicity n/a RfD 3 x 10 -2 mg/kg-day
592 Rotenone 83-79-4 Oral Noncancer Reduced pup weight n/a RfD 4 x 10 -3 mg/kg-day
593 Savey 78587-05-0 Oral Noncancer Hypertrophy of adrenal cortex (both sexes) hematologic effects (males) n/a RfD 2.5 x 10 -2 mg/kg-day
594 Selenious acid 7783-00-8 Oral Noncancer Clinical selenosis n/a RfD 5 x 10 -3 mg/kg-day
595 Selenium and Compounds 7782-49-2 Oral Noncancer Clinical selenosis n/a RfD 5 x 10 -3 mg/kg-day
596 Selenium sulfide 7446-34-6 None Cancer None B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
NA 0 NA
597 Sethoxydim 74051-80-2 Oral Noncancer Mild anemia in males n/a RfD 9 x 10 -2 mg/kg-day
598 Silver 7440-22-4 Oral Noncancer Argyria n/a RfD 5 x 10 -3 mg/kg-day
599 Silver cyanide 506-64-9 Oral Noncancer Weight loss, thyroid effects, and myelin degeneration n/a RfD 1 x 10 -1 mg/kg-day
600 Simazine 122-34-9 Oral Noncancer Reduction in weight gains hematological changes in females n/a RfD 5 x 10 -3 mg/kg-day
601 Sodium azide 26628-22-8 Oral Noncancer Clinical sign (e.g., hunched postures) and reduced body weight n/a RfD 4 x 10 -3 mg/kg-day
602 Sodium cyanide 143-33-9 Oral Noncancer Decreased cauda epididymis weight in male F344/N rats. The RfD for potassium cyanide is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. n/a RfD 1 x 10 -3 mg/kg-day
603 Sodium diethyldithiocarbamate 148-18-5 Oral Noncancer Reduced body weight n/a RfD 3 x 10 -2 mg/kg-day
604 Sodium fluoroacetate 62-74-8 Oral Noncancer Increased heart weight in females and males; decreased testis weight and altered spermatogenesis in males. n/a RfD 2 x 10 -5 mg/kg-day
605 Strontium 7440-24-6 Oral Noncancer Rachitic bone n/a RfD 6 x 10 -1 mg/kg-day
606 Strychnine 57-24-9 Oral Noncancer Toxicity/histopathology n/a RfD 3 x 10 -4 mg/kg-day
607 Styrene 100-42-5 Inhalation Noncancer CNS effects n/a RfC 1 mg/m3
608 Styrene 100-42-5 Oral Noncancer Red blood cell and liver effects n/a RfD 2 x 10 -1 mg/kg-day
609 Systhane 88671-89-0 Oral Noncancer Testicular atrophy n/a RfD 2.5 x 10 -2 mg/kg-day
610 Tebuthiuron 34014-18-1 Oral Noncancer Depressed body weight gain in F1 females n/a RfD 7 x 10 -2 mg/kg-day
611 Terbacil 5902-51-2 Oral Noncancer Increase in thyroid/body weight ratio; slight increase in liver weights; elevated alkaline phosphatase n/a RfD 1.3 x 10 -2 mg/kg-day
612 Terbutryn 886-50-0 Oral Noncancer Hematologic effects in females n/a RfD 1 x 10 -3 mg/kg-day
613 Tetrabromodiphenyl ether 40088-47-9 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
614 2,2',4,4'-Tetrabromodiphenyl ether (BDE-47) 5436-43-1 Oral Noncancer Neurobehavioral effects n/a RfD 1 x 10 -4 mg/kg-day
615 1,2,4,5-Tetrachlorobenzene 95-94-3 Oral Noncancer Kidney lesions n/a RfD 3 x 10 -4 mg/kg-day
616 Tetrachlorocyclopentadiene 695-77-2 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
617 2,3,7,8-Tetrachlorodibenzo-p-dioxin 1746-01-6 Oral Noncancer Decreased sperm count and motility in men exposed to TCDD as boys / Increased TSH in neonates n/a RfD 7 x 10 -10 mg/kg-day
618 2,3,7,8-Tetrachlorodibenzo-p-dioxin 1746-01-6 Oral Noncancer Decreased sperm count and motility in men exposed to TCDD as boys / Increased TSH in neonates n/a RfD 7 x 10 -10 mg/kg-day
619 1,1,1,2-Tetrachloroethane 630-20-6 Inhalation Cancer Hepatocellular adenoma or carcinoma C (Possible human carcinogen) (1986 guidelines)
Inhalation Unit Risk 7.4 x 10 -6 per µg/m3
620 1,1,1,2-Tetrachloroethane 630-20-6 Oral Noncancer Mineralization of the kidneys in males, hepatic clear cell change in females n/a RfD 3 x 10 -2 mg/kg-day
621 1,1,1,2-Tetrachloroethane 630-20-6 Oral Cancer Hepatocellular adenoma or carcinoma C (Possible human carcinogen) (1986 guidelines)
Oral Slope Factor 2.6 x 10 -2 per mg/kg-day
622 1,1,2,2-Tetrachloroethane 79-34-5 Oral Noncancer Increased relative liver weight in rats n/a RfD 2 x 10 -2 mg/kg-day
623 1,1,2,2-Tetrachloroethane 79-34-5 Oral Noncancer Increased relative liver weight in rats n/a RfD 5 x 10 -2 mg/kg-day
624 1,1,2,2-Tetrachloroethane 79-34-5 Oral Cancer hepatocellular carcinomas Likely to be carcinogenic to humans (2005 guidelines)
Oral Slope Factor 2 x 10 -1 per mg/kg-day
625 Tetrachloroethylene (Perchloroethylene) 127-18-4 Oral Noncancer (See Note) n/a RfD 6 x 10 -3 mg/kg-day
626 Tetrachloroethylene (Perchloroethylene) 127-18-4 Oral Cancer Hepatocellular adenomas or carcinomas Likely to be carcinogenic to humans (2005 guidelines)
Oral Slope Factor 2.1 x 10 -3 per mg/kg-day
627 Tetrachloroethylene (Perchloroethylene) 127-18-4 Inhalation Noncancer (See Note) n/a RfC 4 x 10 -2 mg/m3
628 Tetrachloroethylene (Perchloroethylene) 127-18-4 Inhalation Cancer Hepatocellular adenomas or carcinomas Likely to be carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 2.6 x 10 -7 per µg/m3
629 2,3,4,6-Tetrachlorophenol 58-90-2 Oral Noncancer Increased liver weights and centrilobular hypertrophy n/a RfD 3 x 10 -2 mg/kg-day
630 Tetrachlorovinphos 961-11-5 Oral Noncancer Reduced body weight gain, increased liver and kidney weights, and RBC ChE inhibition n/a RfD 3 x 10 -2 mg/kg-day
631 Tetraethyl lead 78-00-2 Oral Noncancer Histopathology of liver and thymus n/a RfD 1 x 10 -7 mg/kg-day
632 Tetraethyldithiopyrophosphate 3689-24-5 Oral Noncancer Depressed RBC and plasma cholinesterase activity n/a RfD 5 x 10 -4 mg/kg-day
633 1,1,1,2-Tetrafluoroethane 811-97-2 Inhalation Noncancer Leydig cell hyperplasia n/a RfC 8 x 10 1 mg/m3
634 Tetrahydrofuran 109-99-9 Inhalation Noncancer Increased liver weight and centrilobular cytomegaly, CNS effects (narcosis) n/a RfC 2 mg/m3
635 Tetrahydrofuran 109-99-9 Oral Noncancer Decreased pup body weight gain n/a RfD 9 x 10 -1 mg/kg-day
636 Thallium (I), soluble salts Various None Cancer None Inadequate information to assess carcinogenic potential (2005 guidelines)
NA 0 NA
637 Thallium acetate 563-68-8 None Cancer None Inadequate information to assess carcinogenic potential (2005 guidelines)
NA 0 NA
638 Thallium carbonate 6533-73-9 None Cancer None Inadequate information to assess carcinogenic potential (2005 guidelines)
NA 0 NA
639 Thallium chloride 7791-12-0 None Cancer None Inadequate information to assess carcinogenic potential (2005 guidelines)
NA 0 NA
640 Thallium nitrate 10102-45-1 None Cancer None Inadequate information to assess carcinogenic potential (2005 guidelines)
NA 0 NA
641 Thallium oxide 1314-32-5 None Cancer None Inadequate information to assess carcinogenic potential (2005 guidelines)
NA 0 NA
642 Thallium selenite 12039-52-0 None Cancer None Inadequate information to assess carcinogenic potential (2005 guidelines)
NA 0 NA
643 Thallium(I) sulfate 7446-18-6 None Cancer None Inadequate information to assess carcinogenic potential (2005 guidelines)
NA 0 NA
644 Thiobencarb 28249-77-6 Oral Noncancer Decrease in body weight, increase in BUN n/a RfD 1 x 10 -2 mg/kg-day
645 Thiophanate-methyl 23564-05-8 Oral Noncancer Decreased body weight, decreased spermatogenesis, and histological evidence of hyperthyroidism n/a RfD 8 x 10 -2 mg/kg-day
646 Thiram 137-26-8 Oral Noncancer Neurotoxicity n/a RfD 5 x 10 -3 mg/kg-day
647 Toluene 108-88-3 Inhalation Noncancer Neurological effects in occupationally-exposed workers n/a RfC 5 mg/m3
648 Toluene 108-88-3 Oral Noncancer Increased kidney weight n/a RfD 8 x 10 -2 mg/kg-day
649 2,4-/2,6-Toluene diisocyanate mixture (TDI) 26471-62-5 Inhalation Noncancer Chronic lung-function decline n/a RfC 7 x 10 -5 mg/m3
650 Toxaphene 8001-35-2 Inhalation Cancer Hepatocellular carcinomas and neoplastic nodules B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 3.2 x 10 -4 per µg/m3
651 Toxaphene 8001-35-2 Oral Cancer Hepatocellular carcinomas and neoplastic nodules B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.1 per mg/kg-day
652 Tralomethrin 66841-25-6 Oral Noncancer Decreased body weight gain in males increased food and water consumption in males and females n/a RfD 7.5 x 10 -3 mg/kg-day
653 Triallate 2303-17-5 Oral Noncancer Increased hemosiderin deposition, serum alkaline phosphatase, and liver weight in females n/a RfD 1.3 x 10 -2 mg/kg-day
654 Triasulfuron 82097-50-5 Oral Noncancer Centrilobular hepatocytomegaly in males n/a RfD 1 x 10 -2 mg/kg-day
655 1,2,4-Tribromobenzene 615-54-3 Oral Noncancer Increased liver-to-body weight ratio and hepatic microsomal enzyme induction n/a RfD 5 x 10 -3 mg/kg-day
656 Tribromochloromethane 594-15-0 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
657 Tribromodiphenyl ether 49690-94-0 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
658 Tributyltin oxide (TBTO) 56-35-9 Oral Noncancer Immunosuppression n/a RfD 3 x 10 -4 mg/kg-day
659 1,1,2-Trichloro-1,2,2-trifluoroethane (CFC-113) 76-13-1 Oral Noncancer Psychomotor impairment n/a RfD 3 x 10 1 mg/kg-day
660 Trichloroacetic acid 76-03-9 Oral Noncancer Hepatocellular necrosis n/a RfD 2 x 10 -2 mg/kg-day
661 Trichloroacetic acid 76-03-9 Oral Cancer Hepatocellular adenomas or carcinomas Suggestive evidence of carcinogenic potential (2005 guidelines)
Oral Slope Factor 7 x 10 -2 per mg/kg-day
662 1,2,4-Trichlorobenzene 120-82-1 Oral Noncancer Increased adrenal weights; vacuolization of zona fasciculata in the cortex n/a RfD 1 x 10 -2 mg/kg-day
663 Trichlorocyclopentadiene 77323-84-3 None Cancer None D (Not classifiable as to human carcinogenicity) (1986 guidelines)
NA 0 NA
664 1,1,1-Trichloroethane 71-55-6 Inhalation Noncancer Performance on neurobehavioral tests n/a RfC 7 mg/m3
665 1,1,1-Trichloroethane 71-55-6 Inhalation Noncancer Liver histopathologic changes n/a RfC 5 mg/m3
666 1,1,1-Trichloroethane 71-55-6 Oral Noncancer Reduced body weight n/a RfD 7 mg/kg-day
667 1,1,1-Trichloroethane 71-55-6 Inhalation Noncancer Performance on neurobehavioral tests n/a RfC 9 mg/m3
668 1,1,1-Trichloroethane 71-55-6 Oral Noncancer Reduced body weight n/a RfD 2 mg/kg-day
669 1,1,1-Trichloroethane 71-55-6 Inhalation Noncancer Performance on neurobehavioral tests n/a RfC 7 mg/m3
670 1,1,1-Trichloroethane 71-55-6 Inhalation Noncancer Performance on neurobehavioral tests n/a RfC 6 mg/m3
671 1,1,1-Trichloroethane 71-55-6 Inhalation Noncancer Performance on neurobehavioral tests n/a RfC 5 mg/m3
672 1,1,1-Trichloroethane 71-55-6 Inhalation Noncancer Liver histopathologic changes n/a RfC 5 mg/m3
673 1,1,2-Trichloroethane 79-00-5 Oral Noncancer Clinical serum chemistry (effects on erythrocytes and depressed humoral immune status) n/a RfD 4 x 10 -3 mg/kg-day
674 1,1,2-Trichloroethane 79-00-5 Inhalation Cancer Hepatocellular carcinoma C (Possible human carcinogen) (1986 guidelines)
Inhalation Unit Risk 1.6 x 10 -5 per µg/m3
675 1,1,2-Trichloroethane 79-00-5 Oral Cancer Hepatocellular carcinoma C (Possible human carcinogen) (1986 guidelines)
Oral Slope Factor 5.7 x 10 -2 per mg/kg-day
676 Trichloroethylene 79-01-6 Oral Cancer Renal cell carcinoma, non-Hodgkin's lymphoma, and liver tumors Carcinogenic to humans (2005 guidelines)
Oral Slope Factor 5.2 x 10 -2 per mg/kg-day
677 Trichloroethylene 79-01-6 Inhalation Cancer Renal cell carcinoma, non-Hodgkin's lymphoma, and liver tumors Carcinogenic to humans (2005 guidelines)
Inhalation Unit Risk 4.8 x 10 -6 per µg/m3
678 Trichloroethylene 79-01-6 Oral Noncancer (See Note) n/a RfD 5 x 10 -4 mg/kg-day
679 Trichloroethylene 79-01-6 Inhalation Noncancer (See Note) n/a RfC 2 x 10 -3 mg/m3
680 Trichlorofluoromethane 75-69-4 Oral Noncancer Survival and histopathology (pleuritis and pericarditis) n/a RfD 3 x 10 -1 mg/kg-day
681 2,4,5-Trichlorophenol 95-95-4 Oral Noncancer Liver and kidney pathology n/a RfD 1 x 10 -1 mg/kg-day
682 2,4,6-Trichlorophenol 88-06-2 Oral Cancer Leukemia B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Oral Slope Factor 1.1 x 10 -2 per mg/kg-day
683 2,4,6-Trichlorophenol 88-06-2 Inhalation Cancer Leukemia B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines)
Inhalation Unit Risk 3.1 x 10 -6 per µg/m3
684 2(2,4,5-Trichlorophenoxy) propionic acid (2,4,5-TP) 93-72-1 Oral Noncancer Histopathological changes in liver n/a RfD 8 x 10 -3 mg/kg-day
685 2,4,5-Trichlorophenoxyacetic acid (2,4,5-T) 93-76-5 Oral Noncancer Increased urinary coproporphyrins n/a RfD 1 x 10 -2 mg/kg-day
686 1,1,2-Trichloropropane 598-77-6 Oral Noncancer Mild lesions in liver, kidney and thyroid n/a RfD 5 x 10 -3 mg/kg-day
687 1,2,3-Trichloropropane 96-18-4 Oral Noncancer Increased absolute liver weight in male rats n/a RfD 4 x 10 -3 mg/kg-day
688 1,2,3-Trichloropropane 96-18-4 Oral Cancer alimentary system squamous cell neoplasms, liver hepatocellular adenomas or carcinomas, Harderian gland adenomas, uterine/cervix adenomas or carcinomas Likely to be carcinogenic to humans (2005 guidelines)
Oral Slope Factor 5 x 10 -1 per mg/kg-day
689 1,2,3-Trichloropropane 96-18-4 Inhalation Noncancer peribronchial lymphoid hyperplasia in male rats n/a RfC 3 x 10 -4 mg/m3
690 Tridiphane 58138-08-2 Oral Noncancer Decreased fertility index and depressed body weight of dams n/a RfD 3 x 10 -3 mg/kg-day
691 Triethylamine 121-44-8 Inhalation Noncancer Inflammation of the nasal passage n/a RfC 7 x 10 -3 mg/m3
692 Trifluralin 1582-09-8 Oral Cancer Combined renal pelvis carcinomas, urinary bladder papillomas and/or thyroid adenomas and carcinomas C (Possible human carcinogen) (1986 guidelines)
Oral Slope Factor 7.7 x 10 -3 per mg/kg-day
693 Trifluralin 1582-09-8 Oral Noncancer Increased liver weights; increase in methemoglobin n/a RfD 7.5 x 10 -3 mg/kg-day
694 1,2,3-Trimethylbenzene 526-73-8 Inhalation Noncancer Decreased pain sensitivity in male Wistar rats n/a RfC 6 x 10 -2 mg/m3
695 1,2,3-Trimethylbenzene 526-73-8 Oral Noncancer Decreased pain sensitivity in male Wistar rats n/a RfD 4 x 10 -2 mg/kg-day
696 1,2,3-Trimethylbenzene 526-73-8 Oral Noncancer Decreased pain sensitivity in male Wistar rats n/a RfD 1 x 10 -2 mg/kg-day
697 1,2,3-Trimethylbenzene 526-73-8 Inhalation Noncancer Inflammatory lung lesions n/a RfC 2 x 10 -1 mg/m3
698 1,2,3-Trimethylbenzene 526-73-8 Inhalation Noncancer Decreased pain sensitivity in male Wistar rats n/a RfC 2 x 10 -1 mg/m3
699 1,2,3-Trimethylbenzene 526-73-8 Inhalation Noncancer Decreased segmented neutrophils n/a RfC 6 x 10 -2 mg/m3
700 1,2,4-Trimethylbenzene 95-63-6 Inhalation Noncancer Inflammatory lung lesions n/a RfC 2 x 10 -1 mg/m3
701 1,2,4-Trimethylbenzene 95-63-6 Inhalation Noncancer Decreased fetal weight n/a RfC 4 mg/m3
702 1,2,4-Trimethylbenzene 95-63-6 Inhalation Noncancer Decreased maternal weight n/a RfC 3 mg/m3
703 1,2,4-Trimethylbenzene 95-63-6 Oral Noncancer Decreased pain sensitivity in male Wistar rats n/a RfD 1 x 10 -2 mg/kg-day
704 1,2,4-Trimethylbenzene 95-63-6 Oral Noncancer Decreased pain sensitivity in male Wistar rats n/a RfD 4 x 10 -2 mg/kg-day
705 1,2,4-Trimethylbenzene 95-63-6 Inhalation Noncancer Decreased pain sensitivity in male Wistar rats n/a RfC 6 x 10 -2 mg/m3
706 1,2,4-Trimethylbenzene 95-63-6 Inhalation Noncancer Decreased pain sensitivity in male Wistar rats n/a RfC 2 x 10 -1 mg/m3
707 1,2,4-Trimethylbenzene 95-63-6 Inhalation Noncancer Decreased clotting time n/a RfC 8 x 10 -2 mg/m3
708 1,3,5-Trimethylbenzene 108-67-8 Inhalation Noncancer Decreased pain sensitivity in male Wistar rats n/a RfC 6 x 10 -2 mg/m3
709 1,3,5-Trimethylbenzene 108-67-8 Oral Noncancer Decreased pain sensitivity in male Wistar rats n/a RfD 1 x 10 -2 mg/kg-day
710 1,3,5-Trimethylbenzene 108-67-8 Inhalation Noncancer Decreased fetal weight n/a RfC 4 mg/m3
711 1,3,5-Trimethylbenzene 108-67-8 Inhalation Noncancer Decreased maternal weight n/a RfC 4 x 10 -1 mg/m3
712 1,3,5-Trimethylbenzene 108-67-8 Oral Noncancer Decreased pain sensitivity in male Wistar rats n/a RfD 4 x 10 -2 mg/kg-day
713 1,3,5-Trimethylbenzene 108-67-8 Inhalation Noncancer Decreased pain sensitivity in male Wistar rats n/a RfC 2 x 10 -1 mg/m3
714 2,2,4-Trimethylpentane 540-84-1 None Cancer None Inadequate information to assess carcinogenic potential (2005 guidelines)
NA 0 NA
715 1,3,5-Trinitrobenzene 99-35-4 Oral Noncancer Methemoglobinemia and spleen-erythroid cell hyperplasia n/a RfD 3 x 10 -2 mg/kg-day
716 2,4,6-Trinitrotoluene (TNT) 118-96-7 Oral Noncancer Liver effects n/a RfD 5 x 10 -4 mg/kg-day
717 2,4,6-Trinitrotoluene (TNT) 118-96-7 Oral Cancer Urinary bladder, transitional cell papilloma and transitional squamous cell carcinomas C (Possible human carcinogen) (1986 guidelines)
Oral Slope Factor 3 x 10 -2 per mg/kg-day
718 Uranium, soluble salts Various Oral Noncancer Initial body weight loss moderate nephrotoxicity n/a RfD 3 x 10 -3 mg/kg-day
719 Urea 57-13-6 None Cancer None Inadequate information to assess carcinogenic potential (2005 guidelines)
NA 0 NA
720 Vanadium pentoxide 1314-62-1 Oral Noncancer Decreased hair cystine n/a RfD 9 x 10 -3 mg/kg-day
721 Vernam 1929-77-7 Oral Noncancer Decreased body weight n/a RfD 1 x 10 -3 mg/kg-day
722 Vinclozolin 50471-44-8 Oral Noncancer Organ weight changes (adrenal and kidney) n/a RfD 2.5 x 10 -2 mg/kg-day
723 Vinyl acetate 108-05-4 Inhalation Noncancer Nasal epithelial lesions n/a RfC 2 x 10 -1 mg/m3
724 Vinyl bromide 593-60-2 Inhalation Noncancer Hypertrophy, basophilic and eosinophilic foci, in the liver n/a RfC 3 x 10 -3 mg/m3
725 Vinyl chloride 75-01-4 Inhalation Cancer Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Inhalation Unit Risk 8.8 x 10 -6 per µg/m3
726 Vinyl chloride 75-01-4 Oral Cancer Total of liver angiosarcoma, hepatocellular carcinoma, and neoplastic nodules A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 7.2 x 10 -1 per mg/kg-day
727 Vinyl chloride 75-01-4 Oral Cancer Total of liver angiosarcoma, hepatocellular carcinoma, and neoplastic nodules A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 7.5 x 10 -1 per mg/kg-day
728 Vinyl chloride 75-01-4 Oral Cancer Total of liver angiosarcoma, hepatocellular carcinoma, and neoplastic nodules A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 1.4 per mg/kg-day
729 Vinyl chloride 75-01-4 Inhalation Cancer Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Inhalation Unit Risk 4.4 x 10 -6 per µg/m3
730 Vinyl chloride 75-01-4 Inhalation Cancer Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Inhalation Unit Risk 8.8 x 10 -6 per µg/m3
731 Vinyl chloride 75-01-4 Oral Cancer Total of liver angiosarcoma, hepatocellular carcinoma, and neoplastic nodules A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Oral Slope Factor 1.5 per mg/kg-day
732 Vinyl chloride 75-01-4 Oral Noncancer Liver cell polymorphism n/a RfD 3 x 10 -3 mg/kg-day
733 Vinyl chloride 75-01-4 Inhalation Noncancer Liver cell polymorphism n/a RfC 1 x 10 -1 mg/m3
734 Vinyl chloride 75-01-4 Inhalation Cancer Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules A (Human carcinogen) (1986 guidelines)
Known/likely human carcinogen (1996 guidelines)
Inhalation Unit Risk 4.4 x 10 -6 per µg/m3
735 Warfarin 81-81-2 Oral Noncancer Increased prothrombin time n/a RfD 3 x 10 -4 mg/kg-day
736 White phosphorus 7723-14-0 Oral Noncancer Parturition mortality; forelimb hair loss n/a RfD 2 x 10 -5 mg/kg-day
737 Xylenes 1330-20-7 Oral Noncancer Decreased body weight, increased mortality n/a RfD 2 x 10 -1 mg/kg-day
738 Xylenes 1330-20-7 Inhalation Noncancer Impaired motor coordination (decreased rotarod performance) n/a RfC 1 x 10 -1 mg/m3
739 Zinc and Compounds 7440-66-6 Oral Noncancer Decreases in erythrocyte Cu, Zn-superoxide dismutase (ESOD) activity in healthy adult male and female volunteers n/a RfD 3 x 10 -1 mg/kg-day
740 Zinc cyanide 557-21-1 Oral Noncancer Weight loss, thyroid effects, and myelin degeneration n/a RfD 5 x 10 -2 mg/kg-day
741 Zinc phosphide 1314-84-7 Oral Noncancer Reduction of food intake and body weight n/a RfD 3 x 10 -4 mg/kg-day
742 Zineb 12122-67-7 Oral Noncancer Thyroid hyperplasia n/a RfD 5 x 10 -2 mg/kg-day
743 n-Butanol 71-36-3 Oral Noncancer Hypoactivity and ataxia n/a RfD 1 x 10 -1 mg/kg-day
744 tert-Butyl Alcohol (tBA) 75-65-0 Inhalation Noncancer Increased severity of nephropathy n/a RfC 5 mg/m3
745 tert-Butyl Alcohol (tBA) 75-65-0 Oral Cancer Renal adenomas and carcinomas, thyroid adenomas Suggestive evidence of carcinogenic potential (2005 guidelines)
Oral Slope Factor 5 x 10 -4 per mg/kg-day
746 tert-Butyl Alcohol (tBA) 75-65-0 Oral Noncancer Increased severity of nephropathy n/a RfD 4 x 10 -1 mg/kg-day
Contact Us to ask a question, provide feedback, or report a problem.